Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the 
Integrase Inhibitor MK -2048 (FAME103)  
 
[STUDY_ID_REMOVED]  
 
Document/IRB Approval Date: April 23, 2020  
  
FAME 103 Protocol Version 1.0 20Dec2019   
 
A RANDOMIZED, DOUBLE BLINDED STUDY OF THE SAFETY AND PHARMACOKINETICS 
OF TWO VAGINAL FILM FORMULATIONS CONTAINING  
THE INTEGRASE INHBITOR MK-2048   
 
DAIDS -ES  [ZIP_CODE]  
 
 
Funding Agency:  
Division of AIDS, US National Institute of Allergy and Infectious Diseases  
US National Institutes of Health  
 
Grant Number: A120249  
 
pI[INVESTIGATOR_88470]: 144816  
IND holder: Sharon Hillier  
Pi[INVESTIGATOR_9109], PA [LOCATION_003]  
 
Protocol Chair:  
Katherine Bunge, MD MPH  
University of Pi[INVESTIGATOR_219356], PA [LOCATION_003]  
 
 
Protocol Co -Chair : 
Sharon Hillier, PhD  
University of Pi[INVESTIGATOR_219356], P A [LOCATION_003]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 
 
Study Site:  
UPMC Magee -Womens Hospi[INVESTIGATOR_530129] o f Pi[INVESTIGATOR_530130], PA  
Phone:  412 -641-4242  
Fax:  412 -641-1133  
 
 
Version 1.0 
December 20, 2019
                                                                                                                    Page 2 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
A randomized, double blinded study of the safety and pharmacokinetics of two 
vaginal film formulations containing the integrase inhibitor MK -2048  
  
Table of Contents  
PROTOCOL SIGNATURE [CONTACT_1783] ………………………………………………………………………[ADDRESS_688491]  OF ABBREVIATIONS AND ACRONYMS  ................................ ................................ .......... 6 
PROTOCOL TEAM ROSTER  ................................ ................................ ................................ .....7 
PROTOCOL SUMMARY  ................................ ................................ ................................ ............ 9 
1 KEY ROLES  ................................ ................................ ................................ ..................... 11 
1.1 Protocol Identification  ................................ ................................ ......................  11 
1.2 Funding  ................................ ................................ ................................ ...........  11 
1.3 Protocol Chair  ................................ ................................ ................................ . 11 
1.4 Laboratory  ................................ ................................ ................................ ....... 11 
2 INTRODUCTION  ................................ ................................ ................................ ............... 13 
2.1 HIV prevention  and microbicides  ................................ ................................ .... 13 
2.2 Integrated Preclinical/Clinical Program  ................................ ...........................  14 
2.3 Rationale  ................................ ................................ ................................ ........  14 
2.4 Safety Data: Placebo Eudragit® platform  ................................ .......................  15 
2.5 Safety and PK Data: MK -2048  ................................ ................................ ........  16 
2.6 Summary ................................ ................................ ................................ .........  18 
3 OBJECTIVES  ................................ ................................ ................................ ................... 18 
3.1 Primary Objectives:  ................................ ................................ .........................  18 
3.2 Primar y Endpoints:  ................................ ................................ ..........................  19 
3.3 Secondary Objectives:  ................................ ................................ ....................  19 
3.4 Secondary Endpoint:  ................................ ................................ .......................  19 
3.5 Explor atory Objectives:  ................................ ................................ ...................  19 
3.6 Exploratory Endpoints:  ................................ ................................ ....................  [ADDRESS_688492] Dispensing  ................................ ................................ ...............  24 
6.6 Concomitant Medications  ................................ ................................ ................  24 
7 STUDY PROCEDURES  ................................ ................................ ................................ ....24 
7.1 Pre-Screening  ................................ ................................ ................................ . 24 
7.2 Visit 1: Screening Visit  ................................ ................................ ....................  24 
7.3 Visit 2: Enrollment  ................................ ................................ ...........................  25 
7.4 Visit 3, 4, 5, 6, 7 and 8: Follow -Up Visits  ................................ .........................  [ADDRESS_688493] Hold  ................................ ................................ ................................ . 33 
8.6 Social Harms Reporting  ................................ ................................ ..................  33 
8.7 Criteria for Early Termination of Study Participation  ................................ ....... 33 
    8.8      Reporting to the FDA ………………………………………………………………33  
9 STATISTICAL CONSIDERATIONS  ................................ ................................ .................. 34 
9.1 Review of Study Design  ................................ ................................ ..................  34 
9.2 Sample Size and Accrual  ................................ ................................ ................  34 
9.3 Study Endpoints  ................................ ................................ ..............................  35 
9.3.1 Primary Endpoint  ................................ ................................ ...........................  35 
9.3.2 Secondary and Exploratory Endpoints  ................................ ..........................  35 
9.4 Blinding  ................................ ................................ ................................ ...........  37 
9.5 Emergency Unblinding  ................................ ................................ ....................  37 
9.6 Rand om Assignment  ................................ ................................ .......................  37 
9.7 Data Monitoring and Analysis  ................................ ................................ .........  37 
9.6.1 Data Monitoring  ................................ ................................ .............................  37 
9.6.2 Primary Endpoint Analysis  ................................ ................................ ............  37 
9.6.3 Secondary and Exploratory Endpoint Analysis  ................................ ..............  37 
9.6.4 Analysis Cohort  ................................ ................................ .............................  38 
10 HUMAN SUBJECTS CONSIDERATIONS  ................................ ................................ ........ 39 
10.1  Special Populations  ................................ ................................ ........................  39 
10.1.1 Men  ................................ ................................ ................................ .............  39 
10.1.2 Children  ................................ ................................ ................................ ....... 39 
10.1.3 Prisoners  ................................ ................................ ................................ ..... 39 
10.1.4 Pregnant women  ................................ ................................ .........................  40 
10.2  Informed Consent Process ................................ ................................ ..............  40 
10.2.1 Risk/Benefit Statement  ................................ ................................ ................  [ADDRESS_688494] Containment ................................ ................................ ...................  45 
12 ADMINISTRATIVE PROCEDURES  ................................ ................................ .................. 46 
12.1  Protocol Registration  ................................ ................................ .......................  46 
12.2  Data Coordination  ................................ ................................ ...........................  46 
12.3  Study Monitoring  ................................ ................................ .............................  46 
12.4  Protocol Compliance  ................................ ................................ .......................  46 
12.5  Investigator’s Records  ................................ ................................ ....................  47 
12.6  Use of Information and Publications  ................................ ...............................  47 
12.7  Training Procedures  ................................ ................................ ........................  47 
REFERENCES  ................................ ................................ ................................ ......................... 48 
APPENDIX 1:  SCHEDULE OF STUDY VISITS AND PROCEDURES  .................  49 
APPENDIX II:  HIV TESTING AGORITHIM  ................................ ...........................  50 
        APPENDIX III:  SAMPLE INFORMED CONSENT…………………… .………… ..…49  
         
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                    Page 5 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
 
 
 
 
Protocol Signature [CONTACT_530195]:   A randomized, double blinded study of the safety and 
pharmacokinetics of two vaginal film formulations containing the integrase inhibitor MK -
2048  
 
DAIDS #:    DAIDS -ES # [ZIP_CODE]  
 
Protocol Date:   20December2019  
 
Protocol Version:   Version 1.[ADDRESS_688495] this study in compliance with 
[LOCATION_002] (US) Health and Huma n Service regulations (45 CFR 46); applicable U.S. 
Food and Drug Administration regulations; standards of the International Conference on 
Harmonization Guideline for Good Clinical Practice (E6); Institutional Review 
Board/Ethics Committee determinations; a ll applicable in -country, state, and local laws 
and regulations; and other applicable requirements (e.g., US National Institutes of 
Health, Division of AIDS) and institutional policies.  
 
 
 
_______________________________________________  
Protocol Chair (PR INT NAME)  
 
 
 
_________________________________________________  
Signature [CONTACT_530196]  
 
 
 
________________________  
Date (Month/Day/Year)  
  
                                                                                                                    Page 6 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 A randomized, double blinded study of the safety and pharmacokinetics of two 
vaginal film formulations  containing the integrase inhibitor MK -2048:  
FAME [ADDRESS_688496] operating procedure(s)  
STI   Sexually transmitted infection  
                                                                                                                    Page 7 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  A randomized, double blinded study of the safety and pharmacokinetics of two 
vaginal film formulations  containing the integrase inhibitor MK -2048:  FAME [ADDRESS_688497]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-6967  
Fax: 412 -641-1133  
Email: [EMAIL_4599]   
 
Sharon Hillier, PhD  
Protocol Co -Chair  
Department of Obstetrics,  
Gynecology and Reproductive Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_688498]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-8933  
Fax: 412 -641-6170  
Email: [EMAIL_5476]  
 
Lisa Rohan, PhD  
Co-investigator  
Department of Pharmaceutical Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_688499]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone: 412 -641-6108  
Fax: 12-641-6170  
Email:  [EMAIL_5477]  
 
 Julie S. Downs, PhD  
Co-investigator  
Dept. of Social and Decision Sciences  
Carnegie Mellon University  
208 Porter Hall (SDS)  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] -3890  
Office:  219 -C Porter Hall  
Phone:  412 -268-1862  
Fax:  412 -268-6938  
Email:  [EMAIL_5482]  
 
 
 
 Bernard Moncla, PhD  
Co-investigator  
Department of Obstetrics, Gynecology and 
Reproductive Sciences  
Magee -Womens Research Institute  
[ADDRESS_688500]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone: 412 -641-6025  
Fax: 412 -641-6170  
Email:  [EMAIL_5479]  
 
Leslie Meyn, PhD  
Biostatistician/Epi[INVESTIGATOR_280922],  
Gynecology and Reproductive Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_688501]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone:  42 -641-4233  
Fax: 412 -641-1133  
Email:  meyn [EMAIL_10111]   
 
Urvi Parikh, PhD  
Co-Investigator  
University of Pi[INVESTIGATOR_9109]  
[ADDRESS_688502]  
S804 Scaife Hall  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone: 412 -648-3103  
Fax: 412 -648-8521  
Email: [EMAIL_10112]  
 
Peter L. Anderson, PharmD  
Co-investigator  
Department of Pharmaceutical Sciences  
Skaggs School of Pharmacy and 
Pharmaceutical Sciences  
University of Colorado Anschutz Medical 
Campus  
V20-C238, Room [ADDRESS_688503].  
Aurora, CO [ZIP_CODE]  
Phone:  303 -724-6128  
Fax:  303 -724-6135  
Email:  [EMAIL_1651]  
 
                                                                                                                    Page [ADDRESS_688504], Clinical  
Microbiology/Virology  
[COMPANY_006] and Co. Inc  
[ADDRESS_688505] Point, PA [ZIP_CODE]  
Tel: 215 652 -6058  
Email: [EMAIL_10113]  
 NIH 
Hans M.L. Spi[INVESTIGATOR_16614], MD  
Sr. Medical Officer, PMPRB/Prevention 
Sciences Program,  
Contractor, Kelly Government Solutions  
DAIDS, NIAID, NIH 
[ADDRESS_688506]  
Room 8B51A  
Rockville, MD [ZIP_CODE]  
Tel:  [PHONE_5830]  
Fax: 240 -627-3465  
Email: [EMAIL_5483]  
 
Jim A. Turpin, PhD   
Branch Chief  
Preclinical Microbicides and Prevention 
Research Branch (PMPRB)  
NIAID/DAIDS  
Room 8B31/MSC [ADDRESS_688507]  
Rockville, MD [ZIP_CODE] -9831  
Phone    (301) 451 -2732  
Fax (240) 627 -3465  
Email: [EMAIL_5484]   
 
Cherlynn Mathias, RN, BSN  
Program Officer/Nurse Consultant  
Prevention Science Program, NIH/DAIDS/PSP  
[ADDRESS_688508], 8B51B MSC 9831  
Rockville, MD [ZIP_CODE]  
Phone:  [PHONE_5831]  
Fax: 240 -627-3465  
Email:  [EMAIL_5485]   
 
Naana Cleland  
Prevention Sciences Program , NIH/DAIDS/PSP  
[ADDRESS_688509], Room 8B27  
Rockville , MD 208 52 
Phone:  240 292 -4779  
Email:  [EMAIL_10114]  
 
Jeanna Pi[INVESTIGATOR_11826], MD  
Sr. Medical Officer  
Clinical Microbicide Research Branch  
PSP/DAIDS/NIAID/NIH  
[ADDRESS_688510]  
Room 8B68  
Rockville, MD [ZIP_CODE]  
Tel: 240 -292-4798  
E-mail: [EMAIL_5486]  
                                                                                                                    Page 9 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
A randomized, double blinded study of the safety and pharmacokinetics of two 
vaginal film formulations containing the integrase inhibitor MK -2048:  
FAME 103  
 
PROTOCOL SUMMARY  
 
Short Title:         FAME 103 
 
Protocol Chair : Katherine  Bunge, MD MPH   
 
Protocol Co -chair:  Sharon Hillier, PhD  
 
Sample Size:  Approximately  48  
 
Study Population:   HIV-uninfected women , 18 – 45 years old  
 
Study Sites:  UPMC  Magee -Womens  Hospi[INVESTIGATOR_307], Pi[INVESTIGATOR_9109], PA   
 
Study Design:  A phase I, 2 arm, single site, randomized clinical  trial  
 
 
 
Study Duration:  Accrual of approximately 48 participants is expected to take 9 months. The 
expected duration of study participation for ea ch participant  will be 
approximately 5-10 weeks.  This includes the screening period.  After 
enrollment, the study duration is 4 weeks  
 
Study Products:  One dose MK-2048  vaginal film (2” x 2” size) . Participants will be 
randomized to one of two formulations - high and low  ammonio 
methacrylate copolymer type B ( Eudragit ®). Both films contain 30mg of 
MK-2048 . 
 
     
Study Regimen:  All participants will be randomized to receive a single dose of a vaginal 
film containing MK -2048 (either the high Eudragit® or low Eudragit® 
formulation). The film will be inserted by a clinician on the day of 
enrollment. Vaginal swabs and plasma will be collected at days 0, 3, 5, 7, 
10, [ADDRESS_688511] insertion sample 
collection (vaginal swab and plasma) at  one or  two time points within 6 
hours of insertion. Genital biopsy samples  and a re ctal swa b will be 
obtained on day 7, and cervicovaginal lavage will be collected at 
screening and day s 14 and 28 .     
 
 
  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  
Screen  Enroll  
Day 0  Day 3  Day 5  Day 7  Day 10  Day 14  Day 28  
                                                                                                                    Page 10 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 Primary Objectives:  
• To assess the safety of a single dose of two formulations of an MK -2048 vaginal film which 
is intended for extende d release of the antiretroviral drug  
 
Endpoints:  
• Grade 2 or higher Adverse Events  
 
Secondary Objectives:  
• To describe the pharmacokinetics of MK -2048 drug at 0, 3, 5, 7, 10, 14, and 28 days 
after film insertion  
• To describe the acceptability of two formulations of the MK -2048 vaginal film  and identify 
qualities associated with higher or lower degrees of acceptability  
 
Secondary Endpoint:  
• MK-2048 concentrations in plasma, cervical tissue homogenate, CVL, rectal and vaginal 
swab eluents  
• Self-reported assessment of qualities of the experience with the films drawn from 
existing survey on microbicidal films, and general acceptability ratings drawn from 
market research methodology  
 
Exploratory Objectives:  
 
• To compare the effects of two formulations of the MK-[ADDRESS_688512] use  
• To describe the pharmacokinetics of Eudragit® polymer  to ensure that polymer 
persistence is proportional to drug release.  
• To describe  the protective effect of MK-[ADDRESS_688513] HIV in an ex vivo  biopsy 
challenge model using one cervical tissue  biopsy  
 
Exploratory Endpoints:  
 
• Vaginal Microenvironment  
• Quantitative vaginal cultures and quantitative PCR for selected microbiota from 
vaginal swab  
• Nugent score from vaginal  swab  
• Levels of anti -HIV viral activity in CVL  
• Levels of glycoproteins and mucins in CVL  
• Levels of biomarkers of innate immunity in CVL  
• Eudragit® pharmacokinetics  
• Eudragit® levels in CV L 
• Ex vivo challenge: HIV infection of cervical tissue as measured by [CONTACT_132370] V-1 p24 replication 
by [CONTACT_530163] -1 exposed cervical biopsies  
 
  
                                                                                                                    Page 11 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 1 KEY ROLES  
 
1.1 Protocol Identification  
Protocol Title:  A randomized, double blinded study of the safety and pharmacokinetics 
of two vaginal film formulations containing the integrase inhibitor MK -2048  
 
Short Title:  FAME 10 3 
  
 
1.2 Funding  
Funding Agency : DAIDS/NIAID/NIH  
              [ADDRESS_688514]  
                                   Rockville, MD [ZIP_CODE] -9831  
 
 
1.3 Protocol Chair  
Protocol Chair:  Katherine Bunge, MD MPH  
Department of Obstetrics,  
Gynecology and Reproductive Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_688515]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-6967  
Fax: 412 -641-1133  
Email: [EMAIL_4599]   
 
 
Protocol Co-Chair:  Sharon L. Hillier, PhD  
   University of Pi[INVESTIGATOR_530131] -Womens Hospi[INVESTIGATOR_307]  
   [ADDRESS_688516]  
   Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
   Phone: 412 -641-6435  
   Fax: 412 -641-1133  
   Email:  [EMAIL_5476]  
  
1.4 Laboratory  
Local/Clinical  Labs : UPMC Presby[CONTACT_530164]  
  [ADDRESS_688517], Room 5521  
   Pi[INVESTIGATOR_9109], PA  [ZIP_CODE] [LOCATION_003]  
                                                                                                                    Page 12 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
Pharmacology : Anderson Laboratory  
   University of Colorado  
   [ADDRESS_688518].  
Aurora, CO [ZIP_CODE]  [LOCATION_003] 
 
Anti-viral 
Studies:  Parikh  Laboratory  
  University of Pi[INVESTIGATOR_530132] -Womens Research Institute  
                                   [ADDRESS_688519]  
  Pi[INVESTIGATOR_9109], PA 15 213 [LOCATION_003] 
 
Microbiology  
Studies:  Hillier Laboratory  
  University of Pi[INVESTIGATOR_530132] -Womens Research Institute  
  [ADDRESS_688520]  
  Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
 
Glycome  
Studies:  Moncla Laboratory  
  University of Pi[INVESTIGATOR_530132] -Womens Research Institute  
  [ADDRESS_688521] arises from a combination of biologic, social, and economic factors.   Women at risk face 
formidable challenges in  protecting themselves from HIV infection, including power differentials, 
gender norms, and economic dependence.  
  
Topi[INVESTIGATOR_530133]. In addition to 
preventing HIV infection, topi[INVESTIGATOR_280925]: affordability and 
female control. Topi[INVESTIGATOR_530134]. Acceptability and utility of topi[INVESTIGATOR_530135] b e maximized by [CONTACT_530165]. For all dosing formulations, safety, stability, and 
efficacy must be established . 
 
Vaginal films are an attractive dosing option for several reasons. In terms of manufacturing, films 
are in expensive, scalable, physically and chemically stable, uniform with regards to product 
content, and amenable to combinations of active ingredients. In terms of use, films are discreet, 
portable, and easy to store. Vaginal films can deliver fixed doses of m icrobicidal agents with 
minimal mess and without an applicator. The small volume of vaginal films may also result in less 
dilution of endogenous antiviral or antibacterial properties of vaginal fluids compared to vaginal 
gels. In studies of spermicidal fil m, women have found vaginal films to be acceptable3-5. When 
Vaginal Contraceptive Film (VCF) was compared to foaming tablets containing nonoxynol -9 (N-
9), contraceptive film was preferred in three different countries 3. Ninety -seven percent of 59 
Mexican women, 60 percent of 52 Dominican women, and 86 percent of 51 Kenyan women 
reported liking contraceptive film.  In particular, they cited the following favorable characteristics: 
ease of use, general feel or comfort, ad ditional lubrication, and lack of side effects 3. Over eighty 
percent of Cameroonian sex workers, who partici pated in a large randomized placebo -controlled 
trial of N -[ADDRESS_688522] s once daily for 7 consecutive days. The film and soft-
gel capsule were chosen significantly more of ten than the tablet as the preferred dosage form 
(39%, 37% and 25%, respectively). In this particular study, film and soft gel were preferred 
because of faster dissolving time and easier insertion5.  In other studies, participants found vaginal 
films to be less messy  than foaming tablets  or gel3,6. The Quatro study was a  randomized 
crossover study conducted in Zimbabwe and South Africa to assess relative preferences of four 
vaginal placebo dosage form s. Two hundred p articipants were asked to use pre ‐coitally inserted 
film, vaginal table  and gel once per week for a month, and a monthly ring (for the entire month) 
during a four ‐month crossover period. Participants subsequently chose one preferred product for 
the final study month.  Preferences  varied within and across countries , and there was no clear 
favorite  reiterating the need for a variety of products to meet different women’ s preferences Just 
under half of the women in Zimbabwe chose the vaginal film and ranked it their favorite  product ; 
in South Africa, the vaginal tablet was the most preferred7. 
 
 
 
                                                                                                                    Page 14 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 2.2 Integrated Preclinical/Clinical Program  
The Film Antiretroviral Microbicide  Evaluation (FAME)  program b rings together an inter -
disciplinary group of research scientists from  four academic institutions: University of Pi[INVESTIGATOR_9109], 
University of Washington, Carnegie Mellon University, and the University of Colorado . The long-
term goal of the program is to  develop and evalu ate an extended delivery vaginal film containing 
an integrase inhibitor which could provide protection from HIV for one week or more following a 
single application. The first iteration of the FAME IPCP established  proof of concept  that vaginal 
films containing the antiretrovirals (ARVs) dapi[INVESTIGATOR_530136] c ould deliver drug to target 
tissues as effectively as gel formulations  of those same ARVs . The second iteration  of the 
program featured FAME -101, a clinica l trial which established proof of concept for the extended 
release placebo vaginal film.  In FAME -101, 64 participants received a single dose of the extended 
release vaginal film and were randomized to the timing of follow -up (3,7,10 or 14 days).  The 
extended release placebo film was well tolerated and visible in 56% of the participants 
randomized to follow -up at 7 days and 25% randomized to follow up at [ADDRESS_688523]. However, the overarching objective of this study is to provide proof of concept that 
an ARV can be delivered in an extended release film formulation to provide drug delivery for 7 
days or more after a single application. Whether or not [COMPANY_006] elects to pursue development of 
MK-2048, the extended release film formulation could provide a novel means to deliver 
antiretroviral drugs vaginally.   
This study is intended  to provide proof of concept that an extended release film could provide 7 
days of  drug delivery . Despi[INVESTIGATOR_530137] -
acting methods, there is still a demand for short acting methods. Some women prefer shorter 
acting interventions because they don’t want long -term systemic exposure to medication. With a 
7-day product which women control themselves, it would be possible to provide protection at 
times of increased risk without necessarily being coitally de pendent. In a survey of 300 women 
conducted as par t of the FAME program , 73% of women preferred a prevention method that 
would be available “when needed” and more women reported that seven day s of protection 
would be preferable to one day  so that a woman m ight use the product once and not have to 
worry about redosing  for a week  (Downs, unpublished data) . 
 
MK-[ADDRESS_688524] both wild type HIV -1 and raltegravir -resistant isolates, it is not currently being used for 
treatment and it has demonstrated a good safety profile in preclinical a nd clinical studie s7. Free 
drug in ectocervical and colorectal explants demonstrated anti -viral activit y. Full protection (6/6 
explants protected) was noted in the colorectal model at 1 μM ; partial protection (4/6 explants 
                                                                                                                    Page 15 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 protected) was noted in the polarized ectocervical model at 100 μM . In an ex vivo challenge 
model conducted in eleven Chinese rhesus macaques, the level of virus growth in the tissue 
biopsies of MK -2048 gel -treated animals (n=5) was lower than that observed in tissues from the 
naïve (n=3) and placebo -treated animals (n=3).  (DAIDS K -28 Gel Study, study identification #: 
[ZIP_CODE] -MK-2048 Biopsy Challenge Study dated February 20, 2019) . Of note,  protection was not 
noted in the ex vivo challenge model performed in the MTN -027 study  of the intravaginal ring  
containing 30 mg of MK -2048 which released drug over 28 days of use .   
 
The current study will compare two extended release films each containing 30 mg of MK -2048 to 
be released over 7 days of use. The two films  having either high (12.8%) or low (6.4%) Eudragit® 
formulation s differ with respect to dissolution rate and spreadability. In in vitro  dissolution testing, 
high Eudragit® film dissolves slower than the low Eudragit® film  and shows decreased 
spreadability . Macaque data included in the investigators’ brochure includes data from pig -tailed 
macaques which support continued release of MK -2048 over a period of 7 days. 8   
 
The safety of the film polymer has been established in a previous clinical trial (FAME -101) and 
the safety of vaginal MK -2048 has been established in preclinical animal studies as well as two 
clinical trials (MTN -027 and MTN -028).   The established safety record of these products supports 
the direct comparison design of this trial without the need for a p lacebo  arm. 
 
The primary objective of the  proposed study will be to evaluate the safety  of two formulations  of 
MK-[ADDRESS_688525] to rate of dissolution.   
 
Secondary objectives include evaluating the pharmacokinetics of the two film formulations as well.  
Understanding the immediate release profile of the films and how long the drug remains in the 
vagina will be integral to the study.  
 
In addition, the products’ acceptability and t he film s’ impact on the vaginal microenvironment, 
cellular immunity , inflammation and innate anti -HIV activity  will also be assessed .  
   
Because  the primary objective  is safety  and one of the secondary objectives is  pharmacokinetics , 
the active  vaginal film will be inserted by a clinician on the day of enrollment .  
  
2.4 Safety Data: Placebo Eudragit® platform  
The Eudragit ® film has a proven safety record . 
 
Pre-Clinical Safety Data   
Safety evaluation of the extended release placebo film was performed in a nonhuman primate 
model.  Six pi[INVESTIGATOR_280933], which is 
double the proposed human dosing (intended dosing is one film per week). In  total, four films 
were delivered to each macaque over fourteen days. The vaginal microbiota, vaginal pH, and 
number of PMNs on gram stained vaginal smears were assessed before the first film placement 
and after the fourth film placement.  The integrity of  the cervicovaginal tissues was assessed by 
[CONTACT_280966]. Of note, there was residual film visible  in the vagina with each 
new film placement. No adverse events were noted by [CONTACT_280967] ; microbiota remained stable 
with no effect noted on the beneficial H202 producing microorganisms; vaginal pH remained 
within normal range; and PMN counts remained within the normal range even after more frequent 
administration than intended for use (Patton, personal communication) . The entire study repor t is 
presented in Appendix IV.  
 
Clinical Safety Data  
                                                                                                                    Page 16 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 FAME -101 was a safety and acceptability study of the high (12.8%) Eudragit ® placebo vaginal 
film. Sixty -four HIV uninfected, healthy women were enrolled. At enrollment  the participants were 
randomized to timing of the  follow -up visit. Participants returned either 3,7,10 or 14 days after film 
placeme nt depending on their randomization  and then a ll participants returned for a final safety 
assessment three weeks after enrollment. Safety assessments, acceptability parameters, and 
changes to the vaginal microenvironment were assessed at each visit. The persistence of the film  
by [CONTACT_530166].  
 
Eight y-four participants were screened and 64 enrolled. The median age was 26.5  years ; 56% 
were white  and 27% non -Hispanic black.  The primary endpoint was Grade 2 or higher AEs. There 
were 6 Grade 2 events; these i ncluded bacterial vaginosis, vaginal itching, pelvic crampi[INVESTIGATOR_007] (2), 
friable cervix and adnexal pain. Of these, only bacterial vaginosis and vaginal itching were 
attributed to study product use.  Forty -seven AEs were reported amongst 64 participants. Thirty -
one participants (48.5%) reported at least one AE; [ADDRESS_688526] one urogenital event. For 
the women randomized to the 3 and 7 day follow up visit approximately 50% of the participants 
had visible film on speculum exam (44% and 56%). In summary, the  high Eudragit® film was very 
well tolerated  with no concerning safety signals.  
 
2.5 Safety and PK Data: MK -2048  
Pre-Clinical Safety  and PK  Data  
MK-2048 was formulated as a gel to evaluate the potential local effects, systemic toxicity and 
toxicokinetics in rats and rabbits when administered intravaginally for 28 days. Gels containing 
0.059%, 0.117%, and 0.234% MK -2048 were developed for daily topi[INVESTIGATOR_530138].  In the 4 -week rat study (study no. 1726 -026) there was no evidence of systemic 
toxicity attributable to MK -2048 following daily intra -vaginal administration for 28 days. MK -2048 
appearance in plasma was rapid, with mean maximum concentrations of 0.38 to 0.76 µM (0.234% 
gel dose) that were achieved by 0.[ADDRESS_688527] dose. However,  MK-2048 disappeared rapi[INVESTIGATOR_530139] (i.e., C24h) that were <LLQ (LLOQ = 0.0108 μM) 
at all doses.  The compound  was well tolerated as there were no untoward local effects in vaginal 
tissues.  Because of the absence of an y local or systemic toxicity in the rat model, the high dose 
gel of 0.234% MK -[ADDRESS_688528] level (NOAEL).   
 
Ten-day (study no. 1726 -020) and 28 -day (study no. 1726 -027) Good Laboratory Practices (GLP) 
intravaginal stud ies were conducted in female rabbits in which gels containing 0.059%, 0.117%, 
and 0.234% MK -[ADDRESS_688529] relationship and the absence of a difference between the placebo and the MK -2048 -treated 
groups, the dose of  0.234% is considered the NOAEL for MK-[ZIP_CODE].  
 
In the 28 -day GLP rabbit study (study no. 1726 -027) there was no evidence of systemic toxicity 
following intra -vaginal administration of MK -2048.  There were no test article -related gross or 
microscopic findings in tissues. Administration of MK -2048 gels at the higher concentrations of 
0.234% and 0.117% had subtle effects on the distal mucosa characterized by [CONTACT_530167]/or focal erosion of distal mucosa.  Therefore, the low concentration of MK -2048 at 0.059% is 
the NOAEL, which is the equivalent of a 5.5 mg/kg total cumulative dose corresponding to a dose 
multiple of 11.  Although findings were reported at the higher dose levels for MK -2048 in the 
proximal mucosa of rabbits, the proximal mucosa in the rabbit is a unique tissue and is not 
representative of vaginal tissues in other species, including women.  In summary, the absence of 
relevant changes in distal mucosa and stratified squamous epi[INVESTIGATOR_530140] 17 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 absence of changes in bo th the rat and sheep models, which are more representative of vaginal 
tissues in women, are more relevant findings.  
Data generated in macaque nonclinical studies provide evidence of local tolerability of MK -2048 
extended release films in the vagina .  Human  2”x2” sized extended release films were produced 
for animal studies. Films were cut to 1”x1” sized extended release film  so as to be  compatible with 
pi[INVESTIGATOR_530141].  In six macaque studies , in which [ADDRESS_688530] concentration administered to macaques during nonclinical studies of MK -2048 
extended release  film was 25  mg. This is comparable to 100  mg of human dose based on 4x 
scaling between macaque and human microbicide products. This has been a general conversion 
factor (2 -4x) used among researchers in this field based on anatomical scaling. At  this dose, no 
local toxicity in vaginal tissue nor adverse events during the follow -up of non -human primates 
were reported by [CONTACT_530168].  Macaques exposed to extended release  
film loaded with 7.5 or 25  mg of MK -2048 experienced good local tolerability (observations with 
colpophotograpy) with no tissue adverse responses .    
The observation of the presence  of the extended release  film in the vagina using 
colpophotography documented the appearance of film product as long as it is distinct from vaginal 
exudate. The presence of the film was observed for a week or more in the majority of animals in 
all nonclini cal studies performed in macaques .  Notably, film product was retained during 
menstruation. Further, in the coital study, the films remained in place even after animals had 
coitus . 
The administration of MK -[ADDRESS_688531] not led to any safety issues and were much lower than those observed in rat nonclinical 
study.  
To compare to these results, no systemic tox icity was reported in oral safety studies   
demonstrating MK -2048 plasma concentrations of 0.443  - 3.1 ng/mL are unlikely to evoke any 
safety issues.8. 
 
Clinical Safety and PK Data  
MTN -027 was a multi -site, single -blind, four -arm, randomized, placebo -controlled Phase 1 safety 
and PK trial of the vicriviroc (VCV) (MK4176) vaginal ring containing 182 mg vicriviroc (MK -4176); 
the MK -2048 vaginal ring, containing 30 mg MK -048; the MK -2048 A vaginal ring, containing 182 
mg vicriviroc  (MK-176) and 30 mg MK -2048; and the Placebo vaginal ring10. The study enrolled 
48 healthy, 18 -45 year  old women who were HIV -uninfected, non -pregnant, sexually abstinent, 
and using adequate contraception. Women were randomized to one of four study regimens in a 
1:1:1:[ADDRESS_688532]. Safety 
was evaluated as the proportion of women with related genitourinary AEs and proportion of 
women with any grade 2 or higher AEs . Secondary objectives were to evaluate accept ability and 
adherence over 28 days of use.  
 
Thirteen Grade 1 and 2 Grade 2 related genitourinary AEs were observed in 9 women. Of the 
Grade 1 AEs, vaginal burning, pruritis, and application site erythema and pain were noted. Both 
Grade 2 related genitourin ary AEs were due to vulvovaginal candidiasis. There were no 
statistically significant differences in the number of participants with related genitourinary AEs or 
any Grade 2 AEs between the placebo arm and treatment arms. There were no Grade 3 or higher 
AEs. 
                                                                                                                    Page 18 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
MK-2048 peak concentrations, from both the single and combination IVR, were substantially 
higher in vaginal fluids than in plasma (30× higher) and rectal fluid  suggesting less risk for 
systemic toxicity  Plasma MK -2048 concentration with the MK-2048 -alone vaginal ring achieved 
peak concentrations more rapi[INVESTIGATOR_530142] (Tmax 
median 27 and 47 hours, respectively), followed by a similar decline in concentration after VR 
removal (median terminal decay half -life of 3 and 2 hours, respectively). The antiviral activity of 
MK-2048 was not correlated with tissue -associated drug concentrations in an ex vivo HIV -1 
challenge assay.   
 
MTN -028 was a phase 1, single -blind, 2 -arm PK trial of 2 combination vaginal rings cont aining 
different dose strengths of VCV and MK -204811. Eighteen w omen were randomized 2:[ADDRESS_688533] -related genitourinary AEs observed in 5 
women. These AEs occurred in 3 participants (23%) in the low -dose ar m (application site pain, 
vulvovaginal pruritis, and dysmenorrhea), and 2 (33%) in the original -dose arm (diarrhea and 
vaginal discharge). There were an additional 7 unrelated grade 2 AEs (5 in the low -dose arm; 2 
in the original -dose arm); no grade ≥[ADDRESS_688534] -related genitourinary AEs (3 of 13 vs 2 of 6 
participants) or any grade ≥2 AEs (6 of 13 vs 3 of 6) between the low -dose and original -dose 
arms, r espectively ( P > .99).  
 
The original dose ring treatment arm offered higher plasma AUC, cervical tissue concentration, 
and greater drug released (based on residual drug levels). Both arms had similar CVF AUCs. 
Plasma and CVF concentrations of MK -2048 decreased  rapi[INVESTIGATOR_530143].  The extended 
release films containing 30 mg of MK -2048 will deliver this drug over a shorter period of time (7 
days) vs the [ADDRESS_688535] a history of safe 
use in the vaginal compartment.  The extended release platform may prove to be an effective drug 
delivery system with the potential to be used with many medications  
 
3 OBJECTIVES  
3.1 Primary Objectives:  
 
                                                                                                                    Page 19 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 • To assess the safety of a single dose of two formulations of an MK -2048 vaginal film which 
is intended for extended release of antiretroviral drugs . 
 
3.2 Primary Endpoints:  
 
• Grade 2 or higher Adverse Events  
 
3.3 Secondary Objectives:  
 
• Pharmacokinetics: To describe the pharmacokinetics of MK -2048 drug at 0, 3,  5, 7, 10, 
14, and 28 days after film insertion  
 
• Acceptability: To describe the acceptability of two formulations of the MK-2048 vaginal film 
and identify qualities associated with higher or lower degrees of acceptability  
 
3.4 Secondary Endpoint:  
• MK-2048 concentrations in plasma, tissue homogenate,  CVL, and rectal  and vaginal 
swab eluents, comparing the two film types  
 
• Acceptability: Self -reported assessment of qualities of the experience with the films drawn 
from existing survey on microbicidal films, and general acceptability ratings drawn from 
market resea rch methodology  
 
3.5 Exploratory Objectives:  
 
• To compare the effects of two formulations of the MK -[ADDRESS_688536] use  
• To describe the pharmacokinetics of Eudragit® polymer  to ensure that polymer 
persistence is proportional to drug release.   
• To describe the protective effect of MK -[ADDRESS_688537] HIV in an ex vivo  biopsy 
challenge model using cervical tissue   
 
3.6 Exploratory Endpoints:  
 
• Vaginal Microenvironment  
• Quantitative vaginal cultures and quantitative PCR for selected microbiota from 
vaginal swab  
• Nugent score from vaginal swab  
• Levels of anti -viral activity in CVL  
• Levels of glycoproteins and mucins in CVL  
• Levels of biomarkers of innate immunity in CVL  
• Eudragit® pharmacokinetics  
• Eudragit® levels in CV L 
• Ex vivo challenge: HIV infection of cervical tissue as measured by [CONTACT_10840] -1 p24 replication 
by [CONTACT_530169] -1 exposed c ervical biopsies  
 
4 STUDY DESIGN  
 
                                                                                                                    Page 20 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 4.1 Identification of Study Design  
This is, single site, double blinded study . 
 
 
4.2 Summary of Major Endpoints  
Grade 2 or higher Adverse Events  
 
4.3 Description of Study Population  
The study population will be HIV -uninfected women who  meet criteria outlined in Section 5.  
 
4.4 Time to Complete Accrual  
Accrual is expected to be completed in approximately 9 months.  
 
4.5 Study Groups  
All participants will be randomized to one of two MK -2048 films: a high Eudragit ® film or a low 
Eudragi t® film.   
 
4.6 Expected Duration of Participation  
The duration of study participation per woman is expected to be approximately 5-10 weeks . This 
includes the screening period.  
 
4.7 Site 
There is a single s tudy site : UPMC Magee -Womens  Hospi[INVESTIGATOR_307], Pi[INVESTIGATOR_9109], PA .   
 
 
[ADDRESS_688538].  
 
5.3 Retention  
Once a participant is enrolled , the study site will make every effort to retain her in follow -up to 
minimize possible bias associated with loss -to-follow -up. The site will implement the following 
procedures to enhance retention:    
 
• Thorough explanation of the study visit schedule and pr ocedural requirements duri ng the 
informed consent process  and re -emphasis at each study visit.      
• Thorough explanation of the importance of both groups to the overall success of the study.  
• Collection of detailed locator information at the study screening  visits, and active review and 
updating of this information at each subsequent visit.  
• Use of appropriate and timely visit reminder mechanisms.  
                                                                                                                    Page 21 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 • Immediate follow -up on missed visits.  
 
Study sites will use a participant tracking mechanism  to facilitate visit scheduling and timely 
identification and follow -up on missed visits.   
 
5.[ADDRESS_688539] meet all the following criteria to be eligible for inclusion in the study:  
 
1) Age 18 through  45 years (inclusive) at screening  
 
2) Able an d willing to provide written informed consent.  
 
3) Willing to use an effective method of birth control throughout the duration of the study.  
Examples of effective methods include:  hormonal methods (o ther than NuvaRing® ), IUD, 
bilateral tubal ligation, same sex partner, partner with a vasectomy, abstinence (defined as 
no vaginal sex for one month prior to screening).   
 
4) Able and willing to provide adequate locator information   
 
5) HIV-uninfected based on testing performed by [CONTACT_280968] (per algorithm in 
Appendix II) 
 
6) In general good health as determined by [CONTACT_7554]  
 
7) Agree to be sexually abstinent , including use of sex toys,  from V2 (Enrollment) until V7 (7 
days after the biopsy visit) and 48 hours prior to all study visits . 
 
8) Agree to refrain from use of vaginal device or produc ts (for example, lubricants, creams, 
suppositories)   throughout participation in the study .   Tampons may be used except between 
V5 (biopsy visit) and V7 (day 14).  
 
9)  Willingness to undergo all study -related assessments and follow all study -related 
procedures  
 
10) At screening and enrollment, agrees not to participate in other research studies involving 
drugs, medical devices, or vaginal products while enrolled in this tri al 
 
11) Participants over the age of 21(inclusive) must have documentation of a satisfactory Pap 
within three years prior to Enrollment consistent with Grade 0 according to the Female Genital 
Grading Table for Use in Microbicide Studies Addendum 1 (Dated Novem ber 2007) to the 
DAIDS Table for Grading Adult and Pediatric Adverse Events, Corrected Version 2.1, July 
2017, or satisfactory evaluation with no treatment required of grade [ADDRESS_688540] -menopausal women would introduce heterogeneity into the population.  
                                                                                                                    Page 22 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
1.) Menopause (as defined as amenorrhea for one year or more without a n alternative eti ology)  
 
2.) Hysterectomy  
 
3.) Participant report of any of the following:  
a) Known adverse reaction to any of the study products (ever)  
b) Non- therapeutic injection drug use in the 12 months prior to Screening  
c) Surgical procedure involving the pelvis in the 60 days prior to enrollment (includes 
dilation and curettage or evacuation, and cryosurgery; does not include cervical biopsy 
for evaluation of an abnormal pap smear)   
d) Participation  in a drug, spermicide and/or microbicide study in the 30 days prior to 
enrollment  
e) Currently pregnant or pregnancy within 42 days prior to enrollment  
f) Currently lactating  
g) Use of a diaphragm, NuvaRing®, or spermicide for contraception  
 
4.) Urogenital infection or suspected infection within 7 days of enrollment including: symptomatic 
cand idiasis, trichomonas vaginalis, and symptomatic bacterial vaginosis; or cervical 
infection, including N. gonorrh oeae (GC) , C. trachomatis  (CT), or mucopurulent cervicitis; 
syphilis; HSV lesions, or other sores ( Note: seropositiv e HSV without active lesions will not 
be excluded); acute pelvic inflammatory disease; urinary tract infection; recent exposure to 
a partner with GC, CT, Trichomonas, syphilis, or NGU  
 
5.) Antibiotic or antifungal therapy (vaginal or systemic) within 7 days  of enrollment  
 
6.) As determined by [CONTACT_978], has any significant uncontrolled active or chronic cardiovascular, 
renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine  *including poorly 
controlled diabetes) , respi[INVESTIGATOR_696], immunologic dis order or infectious disease  
 
7.) Menses -like bleeding  at the time of the Enrollment visit * or expected menses -like bleeding 
within 14 days of the Enrollment visit  
(*Women who have vaginal bleeding at the scheduled Enrollment visit may return at a 
different date to be re -examined and possibly enrolled provided they are still within the 
screening window and meet all criteria.)  
 
8.) Any condition that, in the opi[INVESTIGATOR_689], would preclude provision of consent, 
make participation in the study unsafe, c omplicate interpretation of study outcome data, or 
otherwise interfere with achieving the study objectives  
 
[ADDRESS_688541]  
 
6.1 Regimen  
Each participant will receive one vaginal film  containing MK -2048  in either a high dose Eudragit® 
(12.8%) film or low dose Eudragit®  (6.4%) film   
 
6.2 Administration  
After eligibility is confirmed, site staff  will randomize the participant to one of two film formulations: 
high dose Eudragit® or low dose Eudragit®. The site staff will retrieve the film from the pharmacy. 
                                                                                                                    Page [ADDRESS_688542] Formulation   
Participants will be randomized to  one of two formulations - high (12.8%)  or low (6.4%)  Eudragit ® 
polymer. Both films contain 30mg of MK -2048.  The films are 2” x2.”  
 
Calculated composition of MK -2048 30 mg extended release vaginal film (low ammonio methacrylate 
copolymer type B)  
Component  Quantity 
(mg/film)  Function  
MK-2048  30.0 API 
[INVESTIGATOR_530144] E5 (VIVAPHARM® HPMC E5, 
Hypromellose 2910)  36.7 Film forming 
polymer/base  
Hydroxyethyl cellulose (HEC, NATRASOLTM 250L PHARM)  36.7 Film forming 
polymer/base  
Hydroxypropyl methylcellulose (BENECEL™ K4M HPMC 
Type 2208  45.4 Film forming 
polymer/base  
Hydroxypropyl cellulose (HPC, KLUCEL™ JXF PHARM)  73.4 Film forming 
polymer/base  
Ammonio methacrylate copolymer dispersion type B 
(Eudragit® RS 30D)a   41.5 Extended release 
polymer  
Polyethylene glycol 400 (PEG 400)  39.3 Plasticizer/dispersa nt 
Propylene glycol (PG)  28.7 Plasticizer/dispersant  
Purified Water b 11.0 Solvent  
Total unit weight    
 
Calculated composition of MK -2048 30 mg extended release vaginal film high ammonio methacrylate 
copolymer type B)  
Component  Quantity 
(mg/film)  Function  
MK-2048  30.0 API 
[INVESTIGATOR_530144] E5 (VIVAPHARM® HPMC E5, 
Hypromellose 2910)  30.1 Film forming 
polymer/base  
Hydroxyethyl cellulose (HEC, NATRASOLTM 250L PHARM)  30.1 Film forming 
polymer/base  
Hydroxypropyl methylcellulose (BENECEL™  K4M HPMC 
Type 2208  37.2 Film forming 
polymer/base  
Hydroxypropyl cellulose (HPC, KLUCEL™ JXF PHARM)  60.3 Film forming 
polymer/base  
Ammonio methacrylate copolymer dispersion type B 
(Eudragit® RS 30D)a   68.1 Extended release 
polymer  
Polyethylene glycol 400 (PEG 400)  32.3 Plasticizer/dispersant  
Propylene glycol (PG)  23.6 Plasticizer/dispersant  
Purified Water b 10.[ADDRESS_688543] release testing includes GMP Microbial Limits Testing 
(USP61 /62).  After product release, the packaged study product will be provided to the UPMC 
Magee -Womens Hospi[INVESTIGATOR_78700].   All study product will be available to the study staff through 
the Magee Pharmacy.  
 
                                                                                                                    Page [ADDRESS_688544] returns, destruction (if applicable) and other related issues as 
outlined in instructions for DAID S clinical trial s. All unused study products must be returned to the 
Pharmacy after the study is completed or terminated.    
 
The film is packaged into a foil -lined pouch and stored at room temperature  of 20-25°C (68 -77°F) . 
GMP stability testing will be con ducted for the clinical trial product material. Research and 
development level stability testing is available for the film and shows the product to remain within 
target specifications at all time points evaluated to date.  
 
6.[ADDRESS_688545] Dispensing  
Study products will be dispen sed to clinic staff only upon receipt of a written prescription signed 
by [CONTACT_237269].   
 
6.6 Concomitant Medications  
Enrolled  study participants may use concomitant medications during study participation.  All 
concomitant medi cations, over -the-counter preparations, vitamins and nutritional supplements, 
recreational drugs, and herbal preparations will be recorded on the concomita nt medications  log 
form.   
 
All participants will be counseled to avoid the use of spermicide and other non -study vaginal 
products (other than tampons during menstruation and female condoms)  while participating in the 
study .  Participants who report use of these products will be counseled regarding the use of 
alternative methods ; however reported use of these products does not require any change in 
study  product administration or  follow -up procedures .  Condoms , if provided by [CONTACT_464] , will 
not be coated with any type of spermicide.   
 
7 STUDY PROCEDURES  
This section describes  visit-specific study procedures.     
 
7.1 Pre-Screening   
As part of participant outreach and recruitment strategies, study staff may pre -screen potential 
study participants  (e.g. via telep hone).  During these interactions, study staff may explain the study 
to participants and ascertain elements of presumptive eligibility, to be confirmed at an on -site 
screening visit. If the participant is eligible based on a screening script her name [CONTACT_530197].  If she signs consent, the telephone script will then become part 
of her research record . If she does not sign consent, the form will be de -identified . 
 
7.2 Visit 1: Screening Visit  
Screening may take place up to [ADDRESS_688546] at the Screening visit.     
 
 
 
 
                                                                                                                    Page 25 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
 
   Table 1:  Visit 1 Procedures  
VISIT 1:  SCREENING VISIT  
Component  Procedure/Analysis  
 
 
 
 
 
 
 
ADMINISTRATIVE  • Written Informed Consent  
• Assign Study Number (PTID)  
• Review Eligibility  
• Collect Contact [CONTACT_7171]  
• Medical history and concomitant medications  
• Visit Questionnaire  
• HIV Pre -/Post -Test Counseling  
• Screening Results  
• Protocol counseling  (including effective birth control, 
sexual practices restrictions and vaginal product use)  
• Schedule Next Study Visit, prn  
• Participant Reimbursement  
 
URINE  • Pregnancy test  
• Urine dipstick, as clinically indicated  
SALIVA  • Rapid HIV  
BLOOD  • Confirmatory HIV, as clinically indicated  
 
VAGINAL  • pH 
• Wet Mount, as clinically indicated  
• Trichomonas (NAAT)  
• Vaginal sample  for Future Use * 
 
CERVICAL  • GC/CT (NAAT)  
• Cervical sample  for Future Use * 
• Pap smear, as indicated  
 
 
CVL • Levels of antiviral activity  
• Levels of glycoproteins and mucins  
• Levels of cytokines & innate immunity factors  
• Assessment of drug assay specificity for MK -2048 and 
Eudragit ® 
 
PHYSICAL EXAM  • Physical Exam  
• Vital Signs (BP)  
• Height & Weight  
 
PELVIC EXAM  • Bimanual Exam, as clinically indicated  
• External Genital & Speculum Exam  
      * For participants who have consented to the collection of samples for future use and use of left -over samples for future 
studies.  
 
7.3  Visit 2: Enrollment  
Subjects who meet the inclusion and exclusion criteria following the Screening visit may schedule 
an Enrollment visit.  Care will be taken to schedule the  Enrollment visit at a time when the 
participant is not expecting to be actively bleeding or anticipating her menses within [ADDRESS_688547] of enrollment for this study.  Subjects with menses like  vaginal bleeding at the E nrollment visit 
will not be randomized/enrolled  at that time.  These subjects  may be rescheduled if vaginal 
bleeding re solves before [ADDRESS_688548] insertion.   
 
   Table 2:  Visit 2 Procedures  
VISIT 2:  ENROLLMENT – DAY 0 (Day [ADDRESS_688549] Use)  
Component  Procedure/Analysis  
 
 
 
ADMINISTRATIVE  • Review/Confirm Eligibility  
• Collect/Update Contact [CONTACT_7171]  
• Visit Questionnaire  
• Update medical history and concomitant medications  
• Screening Results  
• Protocol counseling  (including effective birth control, 
sexual practices restrictions and vaginal product use)  
• Assess/Document Adverse Events  
• Schedule Next Study Visit  
• Participant Reimbursement  
ACCEPTABILITY  • Acceptability Questionnaire  (post film insertion)  
BLOOD  • Baseline MK-2048 level  
• Optional MK-2048 level  * 
 
URINE  • Pregnancy test  
• Urine dipstick, as clinically indicated  
 
 
VAGINAL  • pH 
• Wet Mount, as clinically indicated  
• Gram Stain  
• Quantitative Vaginal Culture  
• Quantitative PCR for microbiota  
• MK-2048 level  
• Optional vaginal swab (s) for MK -2048  **  
• Vaginal sample  for Future Use***  
CERVICAL  • Cervical sample  for Future Use *** 
 
PHYSICAL EXAM  • Physical Exam, as clinically indicated  
• Vital Signs (BP)  
 
PELVIC EXAM  • Bimanual Exam, as clinically indicated  
• External Genital & Speculum Exam  
RANDOMIZATION  • Randomization to study product  
 
STUDY PRODUCT  • Study Product Distribution  
• Clinician -inserted with speculum  
*Participants may opt to have one additional blood draw at 1, 2, 3, 4, [ADDRESS_688550] film insertion for MK -2048 levels.  
**Participants may opt to have additional vaginal swabs collected at  one or  two time points (1, 2, 3, 4, 5, or 6 hours) post film 
insertion .  The swabs will be collected by a clinician without a speculum.  
***For participants who have consented to the colle ction of samples for future use and use of left -over samples for future studies.  
 
                                                                                                                    Page 27 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
7.4 Visit 3 , 4, 5, 6 , 7 and 8 : Follow -Up Visit s 
Visit 3 , 4, 5, 6 ,7 and 8 procedures are ou tlined in Table 4.  The windows around these study visits 
are as follows:  
Visit 3 : Day  3 (2-4) 
Visit 4 : Day 5 (5-6) 
Visit 5 : Day 7 (7-8) 
Visit 6 : Day 1 0 (9-12) 
Visit 7: Day 14 (13 -16) 
Visit 8: Day 28 (24 -32) 
Two cervical  biopsies will be obtained at Visit 5 only. A CVL will be performed at Visits 7 and 8. 
Residual drug, if present, will be removed during the CVL at Visit 7. The purpose of Visit 8 is to 
provide a final safety assessment.  
 
   Table 3:  Follow -up Visit Proce dures  
VISIT 3 , 4, 5, 6, 7, 8  FOLLOW -UP VISITS  
Component  Procedure/Analysis  
 
 
ADMINISTRATIVE  • Collect/Update Contact [CONTACT_7171]  
• Visit Questionnaire  
• Update medical history and concomitant medications  
• Protocol counseling  excluding Visit 8 (including effective 
birth control, sexual practices restrictions and vaginal 
product use)  
• Assess/Document Adverse Events  
• Schedule Next Study Visit  (excluding V isit 8)  
• Participant Reimbursement  
ACCEPTABILITY  • Acceptability Questionnaire  (Visit 5 ONLY ; prior to biopsy ) 
BLOOD  • MK-2048 level  
 
URINE  • Pregnancy test  (Visit 5 & 8 and  as clinically indicated ) 
• Urine dipstick, as clinically indicated  
 
 
VAGINAL  • pH 
• Wet Mount, prn  
• Trichomonas (NAAT), as clinically indicated  
• Gram Stain  
• Quantitative Vaginal Culture  
• Quantitative PCR for microbiota  
• Vaginal swab for MK -2048 level  
• Vaginal sample  for Future Use*  
RECTAL  • Rectal swab for MK 2048 (Visit 5 ONLY)  
 
CERVICAL  • GC/CT (NAAT), as clinically indicated  
• Cervical biopsies - two adequate (Visit 5 ONLY)  
• Cervical sample  for Future Use * 
 
 
CVL (Visits 7 and 8 only)  • Levels of antiviral activity  
•   
• Levels of glycoproteins and mucins  
• Levels of cytokines & innate immunity factors  
• MK-2048 level  
• Eudragit® levels  
PHYSICAL EXAM  
 • Physical Exam, as clinically indicated  
• Vital Signs (BP) 
                                                                                                                    Page 28 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
PELVIC EXAM  • Bimanual Exam, as clinically indicated  
• External Genital & Speculum Exam  
      * For participants who have consented to the collection of samples for future use and use of left -over samples for future 
studies.  
 
 
7.5 Participants Who Become Pregnant  
Urine pregnancy tests will be performed at screening, enrollment , Visit 5, Visit 8, and as clinically 
indicated . Participant s who become pregnant will be referred for care . Should the pregnancy be 
diagnosed during study follow -up, pelvic  exams will only be performed to evaluate a participant's 
reported symptom. No genital specimens will be c ollected in a pregnant participant.  
Participants will be terminated from the study but will be contact[CONTACT_530170].  
 
Study staff will report pregnancy details to the  Antiretroviral Pregnancy Registry should an 
enrolled participant become pregnant during follow -up.   
7.6 Interim Visits  
Interim visits may be performed at any time during the study  (and s tudy procedures repeated as 
clinically indicated) , for the following or other reasons:  
 
• For administrative reasons, e.g., a participant may have questions for study staff, or may 
need to re -schedule a follow -up visit.  
• In response to AEs.  When interim contacts or visits are completed in response to 
participant reports of AEs, study staff will assess the reported event clinically and provide 
or refer the particip ant to appropriate medical care.   
• In the event of laboratory processing issues (i.e. inconcl usive STD testing, lost or 
inadequate sample  
• For other reasons at participant request.  
 
 Details of the interim visit will be recorded in the chart notes.  
 
7.7 Clinical Evaluations and Procedures  
Physical exams will include the following assessments:   
 
• Vital signs:  
o Blood pressure  
 
• Measurements of:  
o Weight  (at Screening only)  
o Height (at Screening only)  
  
• Focused physical exam (at Screening only) : 
o General appearance  
o Cardiac exam   
o Respi[INVESTIGATOR_237245]   
o Abdomen   
 
Additional assessments may be performed at the discretion of the examining clinician in 
response to symptoms or illnesses present at the time of the visit/exam.  
 
                                                                                                                    Page 29 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 7.8    Laboratory Evaluations  
 
Local/ Clinical Laboratory  
Urine pregnancy test   
Rapid saliva HIV test  
Wet mount if clinically indicated  
Vaginal pH  
Dipstick urinalysis  if clinically indicated  
Confirmatory HIV testing if indicated   
Pap smear if indicated  
 
MWRI  Laboratories  
Cervical NAAT for chlamydia , gonorrhea  
Vaginal NAAT for trichomonas  
Vaginal Gram stain  
Quantitative vaginal cultures  
Quantitative vaginal PCR for selected microbiota  
Levels of cytokines and innate immunity factors  from CVL 
Levels of glycoproteins and mucins in CVL  
Anti-viral activity from CVL  
Ex vivo HIV challenge of cervical tissue  
 
University of Colorado Lab  
MK-2048 levels in CVL , cervical tissue , rectal fluid, vaginal fluid and plasma  
Eudragit® levels in CVL  
 
7.[ADDRESS_688551] 
operating procedures for proper collection, processing, labeling, handling, transport, and storage 
of specimens.  In cases where laboratory results are not available due to administrative or 
laboratory error, sites are permitted to re -draw and/or re -collect specimens.  
 
7.[ADDRESS_688552] with 
contaminated needles, blood, and blood products, appropriate blood and secretion precautions 
will be employed by [CONTACT_43613][INVESTIGATOR_106423] d handling of all 
specimens for this study as recommended by [CONTACT_530171].  All biological specimens sent to 
the University of Colorado lab will be transported using packaging mandated by [CONTACT_44321] 42 Part 72.  
Biohazardous waste will be contained according t o institutional, transportation/carrier, and all 
other applicable regulatio ns.   
 
8 ASSESSMENT OF SAFETY  AND CLINICAL MANAGEMENT  
 
8.1 Safety Monitoring  
The study site investigators are responsible for continuous close safety monitoring of all study 
participants,  and for alerting the Protocol Team if unexpected concerns arise. A sub -group of the 
Protocol Team, including the Protocol Chair or designee, the DA IDS Medical Officer, and the 
External Safety Monitor  (see section 8.2)  will serve as the Protocol Safety Rev iew Team  (PSRT) . 
Close cooperation among the PSRT and the study site wil l be necessary to monitor participant 
safety and respond to occurrences of toxicity in a timely manner. Appropriate safety monitoring 
                                                                                                                    Page [ADDRESS_688553] review of data and safety monitoring.  This physician,  
independent of the study sponsor , will be available to monitor data from this site.  His/her minimum 
qualifications  will include experience as a physician and experience in the conduct of clinical 
resear ch. This individual will not receive salary or other support from the grant.  The External 
(Independent)  Safety Monitor model has been used s uccessfully for other Magee -Womens  
Hospi[INVESTIGATOR_530145]. The 
proposed individual  will meet th e qualifications outlined above  and have training in the importance 
of the objective treatment of clinical safety data.   
 
The Data Management team for this site will generate data summaries for the Protocol Chair, the 
External Safety Monitor , and the DAIDS M edical Officer  on  at least  a monthly  basis. More 
frequent ad hoc safety reviews can be implemented during the initial enrollment and throughout 
the study as needed. These data summaries will include adverse event, accrual and retention 
data. The External Safety Monitor  will evaluate adverse event data independently as well to 
recommend to the PSRT whether the study protocol should continue as originally designed, 
should be changed, or should be terminated.   
 
Approximately once a month the PSRT will convene via email or  telephone to review adverse 
event data. Only masked safety data will be reviewed by [CONTACT_111153].  If more urgent safety matters 
arise , telephone  calls can occur more frequently.    
 
The IRB will be notified of any seriou s and unexpected adverse events  according to the policies 
outlined in the University of Pi[INVESTIGATOR_9109] I RB Policy and Procedure Manual9. 
 
The following information will be submitted to the University of Pi[INVESTIGATOR_280938] a research protocol , as requ ired by [CONTACT_280973] : 
 
 
• The frequency of monitoring during the  renewal interval, including the dates of data and 
safety monitoring;  
• A summary of any assessment performed to evaluate external factors or other relevant 
information that may have an impac t on the safety of study volunteers or the ethics of the 
research s tudy;  
• A summary of the outcome of procedural reviews conducted to ensure subject privacy and 
research data confidentiality;  
• Any conclusions regarding changes to the anticipated benefit -to-risk ratio of study 
participation and final recommendations related to continuing, changing, or terminating 
the study, with accompanying rationales as appropriate.  
 
Furthermore, should two Grade [ADDRESS_688554].  As such, an AE can be an unfavorable or unintended sign 
(including an abnormal laboratory finding, for example), symptom or disease temporally 
associated with the use of  an investigational product, whether or not considered related to the 
product.  This definition is applied to all groups beginning from the time of randomization.   
 
Study participants will be provided instructions for contact[CONTACT_530172] a ny untoward 
medical occurrences they may experience, except for possible life -threatening events, for which 
they will be instructed to seek immediate emergency care.  Where feasible and medically 
appropriate, participants will be encouraged to seek evaluat ion at UPMC Magee -Womens  
Hospi[INVESTIGATOR_17399] l, where the study clinician s are based, and to request that  a study  clinician be contact[CONTACT_530173].  All participants reporting a  clinically significant untoward medical occurrence 
will be followed either in person or by [CONTACT_237273] (returns to baseline) or 
stabilizes  over a four week period . 
 
Study site staff will document  AEs reported by [CONTACT_530174].   
 
For each study participant, AE documentation and reporting will be undertaken throughout the 
scheduled duration of follow -up, i.e., through Visit 8. 
 
The PI/designee will gra de the severity of each AE and the relationship of the A E to study product:   
 
AE severity will be graded per the DAIDS Table for Grading Adult and Pediatric Adverse Events, 
Version 2.1, July 2017  and the Female Genital Grading Table for Use in Microbicide Studies 
(Appendix 1 , version 1.0, November 2007)  except tha t asymptomatic BV will not be considered 
an AE.  AEs not included in the Female Genital Grading Table will be graded by [CONTACT_280976] 2.1, July 2017 .  In cases where a genital AE is covered in both tables, the 
Female Genital Grading Table for Use in Microbicide Studies will be the grading scale utilized.   
 
The relationship of all reported AEs will be assessed based on the Manual for Expedited 
Report ing of Adverse Events to DAIDS  (Version 2.0, dated January 2010)  and the clinical 
judgment of the PI/designee.   
 
The relationship categories that will be used for this study are:  
Related : There is a reasonable possibility that the AE may be related to the study agent(s)  
Not related : There is not a reasonable possibility that the AE is related to the study agent(s)  
The study products that must be considered when AE relationship s are assigned are the MK-
2048 films.   
 
The DAIDS Table for Grading Adult and Pediatric Adverse Events, th e Female Genital Grading 
Table for Use in Microbicide Studies  is available on the DAIDS Regulatory Support Center (R SC) 
web site: https://rsc.niaid.nih.gov/clinical -research -sites/daids -adverse -event -grading -tables    
 
All AE s will be captured on an AE log.  AEs should be  reviewed at each study visit  and updated 
as needed.   For any Grade 3 or higher AEs  that are continuing at a partic ipant’s study exit visit, 
the Protocol Chair /designee must establish a clinically appropriate follow -up plan for the AE  and 
                                                                                                                    Page [ADDRESS_688555]  2 weeks  after the participa nt’s study exit visit  (Visit 8); additional evaluations also may 
take place at the discretion of the PI/designee.  The same approach must be taken for any AEs 
deemed related to study product that are still ongoing  at the study exit visit  (Visit 8).  For those 
AEs requiring re -assessment, if the AE has not resolved or stabilized at the time of re -assessment, 
study staff will continue to re -assess the participant at least once per month while the study is 
ongoing.     
 
8.[ADDRESS_688556] concerns will be reported to the DAIDS 
MO within 1 business day.  The following information about the critical event will be submitted to 
DAIDS MO :  
 
A detailed description  of the problem  and a ctions the study site is taking or plans to take to 
address the problem, such as suspending participant enrollment, termination of research, revising 
study protocol or inf ormed consent documents, increasing monitoring of the study part icipant, etc. 
Any revisions to the study protocol and informed consent must be reviewed and approved by [CONTACT_530175].  
 
Serious or continuing noncompliance and suspension/termination of IRB approval must be 
reported as critical events as well.  
 
Serious Adverse events will be reported to the DAIDS MO within 24 hours of the site becoming 
aware of the event.  As per the International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Hum an Use ICH definition, a Serious Adverse Event (SAE) is any 
untoward medical occurrence that at any dose:  -results in death,  
 -is life -threatening  
 -requires inpatient hospi[INVESTIGATOR_1081],  
 -results in persistent or significant disability/incapacity,  
 Or 
 -is a congenital anomaly /birth defect  
 
 
8.[ADDRESS_688557] 
event or not.  
 
Adverse events will be elicited at each follow -up visit . Referral to appropriate care will be offered 
to participants as needed  The study site is  well equipped to manage treatment of all sexually 
transmitted infections and vaginitis identified during screening or during study participation excep t 
for HIV.  Participants who are found to be HIV infected will be referred for care.   The PI/designee 
should manage STI/RTI per CDC guidelines, available at http://www.cdc.gov .  Observed single 
dose treatment should be p rovided whenever possible.  Vaginally applied medications should not 
be used if possible.  
 
                                                                                                                    Page [ADDRESS_688558] participant privacy and confidentiality, it is 
possible that participants' involvement in the study could become known to others, and that social 
harms may result (i.e., because participants could become known as HIV -infected or at "high risk" 
for HIV infection). For example, participants could be treated unfairly or discriminated against, or 
could have problems being accepted by [CONTACT_530176]/or communities and/or employer.  
 
Social harms that are judged by [CONTACT_530177].  In the event that a participant reports social harm, every effort will 
be made by [CONTACT_18117], and/or 
referral to appropriate resources for the safety of the participant as needed  
 
8.7 Criteria for Early Termination of Study Participation  
Participants may voluntarily withdraw from the study for any reason at any time.  The Site 
PI/designee also may withdraw participants from the study to protect their safety and/or if they 
are unwillin g or unable to comply with required study procedures . Participants also may be 
withdrawn if the study sponsors, government or regulatory authorities, including  the Office of 
Human Research Protections (OHRP), or site IRBs/ECs terminate the study prior to its planned 
end date.  Every reasonable effort is made to complete a final evaluation of participants who 
withdraw or are withdrawn from the study prior to comp leting follow -up.  Study staff members will 
record the reason(s) for all withdrawals in participants’ study records.   
 
8.8 Reporting to the FDA  
The IND holder will be responsible for reporting any safety concerns to the FDA.   
                                                                                                                    Page 34 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
9 STATISTICAL CONSIDERATIONS  
 
9.1 Revi ew of Study Design  
 
The primary aim of this study is to assess the safety of a single dose of a MK -2048 vaginal film.  
All participants will be randomized to receive a single dose of a vaginal film containing MK -2048 
(either the high Eudragit® or low Eudragit® formulation). The film will be inserted by a clinician 
on the day of enrollment. Vaginal swabs and plasma will be collected at days 0, 3, 5, 7, 10, 14 
and 28. Rectal swab and g enital biopsy samples will be o btained on day 7 and cervicovaginal 
lavage will be collected at screening , day 14  and day 28 . 
 
9.2 Sample Size and Accrual  
 
The primary aim of the study is to assess the local and systemic safety of a single dose of two 
formulations of an MK -2048 vaginal film. The primary endpoint is the proportion of participants 
who experience a Grade 2 or higher adverse event. The proposed t otal sample size is N=48 
divided into 2 arms (low and high Eudragit® content assigned at a 1:1 ratio).   Based on previous 
studies of vaginal products conducted at the study site, the accrual of [ADDRESS_688559] bino mial probability of observing Grade 2 or higher adverse 
events. Table 4 gives the upper and lower bounds for the 95% exact binomial confidence intervals 
of the true Grade 2 or higher adverse event rate at all possible numbers of observed events in a 
group of size 24 or in the full cohort of 48. Note that the results for more than 50% of events in 
each group are not listed, but by [CONTACT_237276] 1 - the listed rate and 95% CI for 
the number of non -events. If none of the 48 subjects experience G rade 2 or higher adverse 
events, the 95% exact 2 -sided upper confidence bound for the Grade 2 adverse event rate is 
7.4%. In a previous study of a single dose of the high Eudragit® content placebo film, 6 grade 2 
adverse events were reported in a cohort of  64 women for an event rate of 9.4%. If similar event 
rates are observed in the proposed study, we will be able to rule out grade 2 or higher adverse 
event rates greater than 22.6% in the full cohort and 32.4% in each study arm.  
 
 
 
TABLE 4:  95% confidence  intervals for the true rate at all possible observed Grade 2 or higher 
adverse event rates  
 
 
Number of 
observed 
events  Rate (95% CI)  Number of 
observed 
events  Rate (95% CI)  
0/24 0 (0, 14.2%)  0/48 0 (0, 7.4%)  
1/24 4.2% (0.1%, 21.1%)  1/48 2.1% (0%, 11.1%)  
2/24 8.3% (1.0%, 27.0%)  2/48 4.2% (0.5%, 14.3%)  
3/24 12.5% (2.7%, 32.4%)  3/48 6.2% (1.3%, 17.2%)  
4/24 16.7% (4.7%, 37.4%)  4/48 8.3% (2.3%, 20.0%)  
5/24 20.8% (7.1%, 42.2%)  5/48 10.4% (3.4%, 22.6%)  
                                                                                                                    Page 35 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 6/24 25.0% (9.8%, 46.7%)  6/48 12.5% (4.7%, 25.2%)  
7/24 29.2% (12.6%, 51.1%)  7/48 14.6% (6.1%, 27.8%)  
8/24 33.3% (15.6%, 55.3%)  8/48 16.7% (7.5%, 30.2%)  
9/24 37.5% (18.8%, 59.4%)  9/48 18.8% (8.9%, 32.6%)  
10/24  41.7% (22.1%, 63.4%)  10/48  20.8% (10.5%, 35.0%)  
11/24  45.8% (25.6%, 67.2%)  11/48  22.9% (12.0%, 37.3%)  
12/24  50.0% (29.1%, 70.9%)  12/48  25.0% (13.6%, 39.6%)  
  13/48  27.1% (15.3%, 41.8%)  
  14/48  29.2% (17.0%, 44.1%)  
  15/48  31.2% (18.7%, 46.3%)  
  16/48  33.3% (20.4%, 48.4%)  
  17/48  35.4% (22.1%, 50.5%)  
  18/48  37.5% (24.0%, 52.6%)  
  19/48  39.6% (25.8%, 54.7%)  
  20/48  41.7% (27.6%, 56.8%)  
  21/48  43.8% (29.5%, 58.8%)  
  22/48  45.8% (31.4%, 60.8%)  
  23/48  47.9% (33.3%, 62.8%)  
  24/48  50.0% (35.2%, 64.8%)  
 
 
9.3 Study Endpoints  
9.3.1 Primary Endpoint    
Grade 2 Adverse Events  
The safety/toxicity endpoint is clinical or laboratory evidence of a Grade 2 or higher Adverse Event 
as defined by [CONTACT_280979], Version 2. 1, July 
2017  and the Female Genital Grading Table for Use in Microbicide Studies (Appendix 1 to the 
DAIDS Table for Grading Adult and Pediatric Adverse Events, (Dated November 2007 ). 
9.3.2 Secondary and Exploratory Endpoint s 
The secondary and exploratory endpoint s of this study are as follows:  
 
Secondary: MK-[ADDRESS_688560] -enrollment time -points 
through Visit 8  
 
Secondary: Acceptability  
Reports of overall acceptability of the film and qualities of the experience with the film will be 
measured using a self -report survey drawing items from two sources. Overall acceptability is 
measured using standard language in market research methodology, each using a 5 -point 
agreement scale followed by [CONTACT_530178]-ended explanation. Assessment of film -specific qualities of 
the experience is assessed by a 9 -item s cale drawn from previous research with participant -
inserted films. Questions assess perceptions of leaking, vaginal dryness, and sensation of the 
film inside the vagina during and after insertion.  
Exploratory: Vaginal Microenvironment  
Given that there is n o non -product use arm, participants will serve as their own control. 
Assessment of baseline microenvironment will take place d uring the Enrollment visit with the 
                                                                                                                    Page [ADDRESS_688561] wit h mucins and may alter their structure and function. These alterations may be 
detected with lectins, which are sugar specific binding molecules, and can be bound to reporter 
molecules (such as horseradish peroxidase) in an ELISA type assay.  
 
Nugent Score  
Clinically significant changes in vaginal flora will be evaluated by a change in the Nugent score 
baseline (Visit 2, pre -exposure) through Visit 7.  The Nugent score is graded 1 to 10 as follows:  
Normal, 0 to 3  
Intermediate, 4 to 6  
BV, 7 -10 
 
Any shift from normal at baseline to intermediate or BV at Visit 3, 4, 5, 6, 7 , or 8  or shift from 
intermediate or BV to normal at  Visit 3, 4, 5, 6, 7 , or 8  will be considered a scientifically  meaningful 
change in vaginal microbiota .   
 
Quantitative vaginal cultures  and quantitative PCR  
Meaningful changes will be defined by [CONTACT_55559] 1 log changes in dominant 
members of the microbiota, including Lactobacillus  species, Gardnerella  vaginalis , key anaerobic 
microorganisms, Enterococcus  species, Escherichia coli , Staphylococcus aureus , Group B 
Streptococcus , and Candida  species.  
 
Levels of anti -viral activity    in CVL  
In-vitro anti-HIV activity will be determined by [CONTACT_280980] -bl assay.  
 
The TZM -bl assay will determine HIV -1 infection by [CONTACT_280981]. To 
assess the potency of the CVL, serial dilutions will be made and tested to determine the IC 50. 
 
Levels of biomarkers of innate immunity  
Changes in cervical cytokine expression and innate immunity factors in cervicovaginal lavage will 
be assessed.  Changes within each group will be reported.  The factors to be analyzed will be 
determined on the scientific evidence at the time of the analysis . 
 
Exploratory: Pharmacokinetic (PK)/ Persistence of Eudragit® in CVL  
Persistence of polymer will be determined as detected levels of polymer in vaginal fluid collected 
through cervicovaginal lavage.  
 
Exploratory: Ex vivo challenge  
HIV infection of cervic al biopsies as measured by [CONTACT_10840] -[ADDRESS_688562] to Eudragit® content . Evaluators of the study endpoints will also be 
blinded to the film formulation.  
 
 
9.5 Emergency Unblinding  
The Principal Investigator [INVESTIGATOR_530146], without prior 
consultation of the PSRT. Details  of emergency unblinding are specified in an SOP.  
 
9.6 Random Assignment  
The randomization scheme will be generated and maintained by a m ember of the Data 
Management Center  at the study site. and supplied to the Pharmacy.  Women will be randomized 
to one of the two arms at a 1:[ADDRESS_688563] packages 
will include sealed envelopes enclosing documentation of the randomized assignment to  film 
formulation . The randomization scheme will be created for a total of 54 participants; the overage 
will be created to compensate for participant wit hdrawals or unusable products.  
 
9.7 Data Monitoring and Analysis  
9.7.1 Data Monitoring  
This clinical trial will be conducted in compliance with the protocol, GCP guidelines, and applicable 
regulatory requirements.  All research charts are maintained in locked files in a locked room. The 
research staff, under the direction of the primary investigator, will create and maintain electronic 
database s using REDCap (Research Electronic Data Capture) which is a secure, web -based 
application designed for clinical trial data collection  that is validated for each study protocol . The 
database s will be backed up every night onto the University of Pi[INVESTIGATOR_9109]’s server’s back -up 
system .  Appropriate firewall and virus scanning software are installed and updated routinely by 
[CONTACT_530179].  
 
This study will utilize electronic data capture. Site staff will enter data as collected directly into a 
data entry system.  Study data management staff will review the electronic data elements for 
completeness and accuracy.  If there are any responses that are incomplete, unclear, or 
inconsistent with related data elements, the staff person will speak with the c linician in question 
as soon as possible to resolve the problem.  If necessary, the study staff will make the appropriate 
change in the electronic database which tracks time and date if a change is made.   
 
9.7.[ADDRESS_688564] using frequencies  and percent . Individual participants will contribute once to the 
calculation of event rates. Differences in the prevalence of adverse events between the study 
arms will be assessed using Fisher’s exact test.  
 
9.7.[ADDRESS_688565] deviations  or medians  and ranges will be provided for continuous data. Methods for 
the analyses of the secondary endpoints are described below.  
                                                                                                                    Page 38 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
Student’s t - and Mann -Whitney U  tests will be used, where appropriate, to evaluate differences 
in the following continuous variables between the study arms: MK-[ADDRESS_688566] -exposure changes in the above endpoints will also be evaluated using 
Student’s t - and Mann -Whitney U  tests, where appropriate, while paired Student’s  t- and 
Wilcoxon signed -rank tests will be used to evaluate these changes within each study arm. 
Mixed effects l inear regression will be used to evaluate associations between days of exposure 
to study product and these outcomes.  
 
Nugent score will be categorized as follows: normal (score 0 -3), intermediate (score 4 -6), and 
bacterial vaginosis (score 7 -10). Differences in the categorized Nugent score pre and post 
exposure levels  will be evalu ated using Fisher’s exact , while McNemar’s tests will be used to 
evaluate pre - to post -exposure shifts between normal (score 0 -3) and abnormal (score 4 -10) 
vaginal microflora within each study arm. Generalized estimating equations will be used to 
evaluate differences in the marginal post exposure prevalence of bacterial vaginosis between the 
two film formulations.  
 
Prevalence of microorganisms at each visit as assessed through culture and qPCR will be 
compared between the study arms using Fisher’s exact tests, while pre - to post -exposure shifts 
will be evaluated within each group using McNemar’s tests. Differences between the study arms 
in the quantity of microorganisms at each visit, as well as the change in quantity, will be evaluated 
using Mann -Whitney U tests. Meaningful changes will be defined by [CONTACT_280982] 1 
log changes in dominant members of the micro biota , including Lactobacillus  species by 
[CONTACT_956] (qPCR) , Prevotella  species by [CONTACT_62865] , Gardnerella vaginalis  (qPCR) , Atopobium 
vaginae  (qPCR) and Megasphaera  phylotype I) qPCR).  Candida species, facultative gram 
negative rods , staphylococci and streptococci will be evaluated by [CONTACT_530180] . 
Fisher’s exact tes ts will be used to evaluate differences in these changes between study arms.   
Mixed effects l inear regression (for continuous outcomes) and generalized estimating equations 
(for binary outcomes) will be used to evaluate associations between days of exposur e to study 
product and these outcomes.  
 
Descriptive statistics will be performed for HIV infection of cervical biopsies as measured by [CONTACT_10840] -
1 p24 replication for each study arm and the combined cohort. Differences in HIV -1 p24 replication  
between study arms  will be evaluated using Student’s t -or Mann -Whitney U test, as appropriate.   
 
9.7.4 Analysis Cohort  
The intent -to-treat cohort (ITT) will be defined as those who were randomized .  It will be used for 
analyses of baseline characteristics, protocol deviations and violations, and trial conduct. The 
evaluable cohort (Eval) is a subs et of ITT  participants. Evaluable participants will be defined as 
participa nts who complete the Screening and Enrollment visits and return for the ir day 7 visit 
within the window  for a safety assessment .  Non-evaluable participants will be replaced.   
 
TABLE 5: Statistical Analysis Plan  
Endpoint  Variable  Statistics  
Primary   
Adverse Events  Frequency,  Percent  
Secondary  MK-2048 concentration  Mean, SD, Median, Ran ge, 
Acceptability  Frequency, Percent  
                                                                                                                    Page 39 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 Exploratory  Persistence of Eudragit® in CVL  defined 
as any concentration above the lower 
limit of quantification  Mean, SD, Median, Range   
Levels of glycoproteins and mucins, in 
CVL Mean, SD, Median, Range  
Antiviral activity in CVL  Mean, SD, Median, Range  
 
Change in vaginal flora (Nugent score)  Frequency, Percent, Median, 
Range  
 
Culture/qPCR results from vaginal 
organisms  - prevalence  Frequency, Percent  
Culture/qPCR results from vaginal 
organisms  - concentration  Mean, SD, Median, Range  
 
Change in cytokine and innate immunity 
factors  Mean, SD, Median, Range  
HIV infection of cervical biopsies  in ex 
vivo challenge  Mean, SD, Median, Range  
[ADDRESS_688567].   
 
10.1.2 Children  
The NIH has mandated that children be included in research trials when appropriate.  This study 
will enroll women aged 18 to 20 who are able to give informed consent.  This  study meets 
“Justifications for Exclusion” criteria for younger children as set forth by [CONTACT_18121].  Spe cifically, "the 
research topic to be studied is irrelevant to (young) children" and "a separate, age -specific study 
in (adolescent) children is warranted  and preferable" at a later time . 
 
10.1.3 Prisoners  
Prisoners will not be included in this study (for screening or enrollment).  Any participants 
incarcerated  during the course of participation in the trial will not be followed during their 
incarceration  and will be discontinued from the study.  Participants who have been released from 
                                                                                                                    Page [ADDRESS_688568] their willingness to continue study participatio n.   
 
10.2.1 Risk/Benefit Statement  
Risks  
It is not expected that this trial will expose human subjects to unreasonable risk.  The intervention 
used in this study is unlikely to cause uncomfortable side effects and is only given once . However, 
there may be unknown risks or side effects associated with the use of the vaginal film.  Some 
women who used the film in other studies have reported vaginal discharge, and irritation and 
discomfort.  Women in studies involving the MK-[ADDRESS_688569].  Only the vaginal candidiasis was Grade 2; the 
other AEs were Grade 1.  
 
Below is a list of potential risks of participation.  There may be other risks associated with 
participation that are not yet known.  
Procedure  Risk  
Pregnancy Test  • Anxious or nervous having test or waiting for results  
• Denial, depression or worry with une xpected positive result  
Pelvic Exam  • Discomfort with speculum  
Genital and rectal 
specimens  • Minimal discomfort from collection of specimens  
Cervical Biopsy  • Generally well tolerated but may ca use pain (or pi[INVESTIGATOR_38633])  
• Crampi[INVESTIGATOR_530147]  
o Crampi[INVESTIGATOR_530148]  
o May take ibuprofen prior to biopsy to minimize crampi[INVESTIGATOR_007]  
• Vaginal spotting or bleeding for a couple days  
o Typi[INVESTIGATOR_15120] a period but if heavier, instructed to 
contact [CONTACT_464]  
• Infection of biopsy area  
                                                                                                                    Page [ADDRESS_688570] study staff  
• A cut in the vagina can increase  the risk of getting HIV if exposed  
• Risk of dislodging an IUD (if present)  
o If displaced, a new one would be inserted at no charge  
Vaginal use of  
MK 2048 film  • Vaginal discharge , irritation, discomfort  
• Vaginal burnin g, itching, redness and/or pain   
• Yeast or bacterial infection  
• Allergic reaction  
Blood draw  • Bruising, soreness, pain/discomfort, bleeding, infection at the site  
• lightheadedness, fainting  
Participation in 
research , 
collection and 
storage of private 
health 
information, 
biospecimens and 
internet 
communication * • Inconvenient  
• Breach of confidentiality  
Questionnaires  • Discomfort with personal nature of questions  
 
STD/HIV testing  • Worry or anxiety  
• Sadness, depression or denial with a positive test result  
o Positive gonorrhea and chlamydia test results will be reported 
to the Allegheny County Health Department  according to the 
Commonwealth of Pennsylvania reporting requ irements  
o May be contact[CONTACT_530181]  
*We will make reasonable efforts to protect the privacy of information on social media. Each platform has 
their own privacy policies and terms of use that may change at any time. The Univ ersity of Pi[INVESTIGATOR_530149]. 
Participants  information may not remain private. Participants will be instructed to visit site privacy policies 
and update privacy settings , as necessary . Social media retains information shared across accounts for an 
unknown length of time and it may be shared with others including targeted advertisers.  
 
Pregnancy, Breastfeeding and Sexual Practices  
The vaginal film is not a birth control method.  We do not know what effect the study drug may 
have on pregnancy, including the effect of the study drug on the fetuses of women who use the 
vaginal film when pregnant, or the babies of women who use the vagi nal film when breastfeeding.  
Because of this, pregnant women and women who are breastfeeding may not join this study.  
Women who join the study must agree to avoid sexual intercourse from V2 (enrollment) until V7 
(7 days after the biopsy visit)  as well as  [ADDRESS_688571] scheduled pregnancy tests while in the study. Effective methods of birth 
control include hormonal methods (like "the pi[INVESTIGATOR_4382]" or Depo -Provera injections), the IUD, sterilization 
(or "tied tubes"), abstinence (or not having sex), same sex partner, or having a partner who has 
had a vasectomy . Effective methods of birth control cannot include use of a diaphragm, NuvaRing, 
or spermicide . Participants  must agree to use an effective  method of birth control until the last 
study vis it, approximately 4 weeks after enrollment .  
 
In the unlikely event that a participant  become s pregnant during the study, study staff will refer 
her to available medical care and other services as needed .  The study does not pay for this care.  
                                                                                                                    Page 42 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 Participants  will be terminated from the study;  however , since the  outcome of the pregnancy is 
important to study staff;  women  will be followed through the outcome of the pregnancy.  
 
If a participant  were to  become HIV infected while using the study product, the HIV virus may 
develop resistance to MK -2048.  Developi[INVESTIGATOR_270196] -[ADDRESS_688572] exams and HIV/STD testing as part of 
participation in this study . 
 
10.3 Incentives  
Volunteers will not be charged for any of the study visits, study supplies or examinations.  There 
are no costs to participants in this study.  Pending IRB approval of these compensation guidelines, 
women will be compensated for their time and inconvenience and for their travel needs while 
participating in the protocol.  The approved amounts of compensation  for the time commitment of 
participants  will be given out at each visit.  The visits will be pro -rated and partial payment given 
in the event that the participant only completes a portion of the study visits.  The following 
proposed compensation amounts were created based on common institutional practice for studies 
investigating vaginal products, as well as studies utilizing observation p eriods in the Clinical 
Translational Research Center.  
 
Visit V1 V2 V3 V4 V5 V6 V7 V8 
Compensation  $30 $40 $30 $30 $100  $30 $30 $40 
Incentive if all visits in window         $40 
Optional procedures   *       
* V2 INCLUDES OPTIONAL SAMPLING: Two vaginal swabs collected without a speculum and 
one blood sample collected following film insertion.   
o Optional collection times are at 1, 2, 3, 4, 5, or 6 hrs.   
o Additional compensation will be provided for each samp le collected ($10 per vaginal 
swab and $20 for blood draw plus an additional $10 for each sample collected between 
4 – 6 hours).  
 
Total compensation for all required visits = $370 .  Potential compensation for all visits, including 
the maximum compensation for optional visits = $440.  
 
If a participant completes a visit outside of the protocol window for that visit, $[ADDRESS_688573] and Compliance Office, 
the Office of Human Research Protections, and/or the University of Pi[INVESTIGATOR_530150]’s health information.  Each member of the staff has log -on identification and 
password, l ogs off before leaving a computer screen unattended, and closes their office door 
when out of the office.  All research records will be kept for a minimum of seven  years following 
closure of this study  (per University of Pi[INVESTIGATOR_280941]) .    
 
10.[ADDRESS_688574] may discontinue this study at any 
time.  Ongoing safety monitoring will track the i ncidence of AEs and EAEs.  In the event of an 
abnormal number of reported AEs and/or EAEs judged to be  related to study product  the External 
Safety Monitor  will contact [CONTACT_079] [INVESTIGATOR_280942] a temporary hold on further 
enrollment.  
[ADDRESS_688575] CONTAINMENT  
 
11.1 Laboratory Specimens  
Laboratory specimens will be handled in a manner consistent with institutional, OSHA, and GLP 
guidelines.  Study staff members are trained in the appropriate handling of laboratory specim ens.  
Samples such as uri ne that will be divided for multiple analyses will be divided according  to site 
SOP.  
   TABLE 6:  Laboratory Test Methods  
SAMPLE  METHOD  LABORATORY  
 
URINE  Pregnancy test  Clinical Research Center  
CLIA #39D1031322  Urine dipstick  
 
SALIVA  Rapid HIV  Clinica l Research Center  
CLIA #39D1031322  
 
BLOOD  Confirmatory HIV  
 
 UPMC Presby[CONTACT_280983]# 39D0911193  
MK-2048 Level  University of Colorado  
(non-diagnostic laboratory)  
RECTAL  MK 2048 Level  University of Colorado  
(non-diagnostic laboratory)  
 
 
 
 
VAGINAL*  pH Clinical Research Center  
CLIA #39D1031322  Wet Mount  
  
 
Magee -Womens Research Institute  
CLIA #39D1004688  Trichomonas (NAAT)  
Gram Stain  
Quantitative Vaginal Culture  
Quantitative PCR for 
microbiota  
MK 2048 Level  in CVL  University of Colorado  
(non-diagnostic laboratory)  
 
  
GC/CT (NAAT)  Magee -Womens Research Institute  
CLIA #39D1004688  
                                                                                                                    Page 44 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
CERVICAL*   
Cervical biopsy tissue for ex 
vivo challenge  Magee -Womens Research Institute  
(non-diagnostic laboratory)  
Cervical biopsy tissue for 
MK 2048 level  University of Colorado  
(non-diagnostic laboratory)  
Pap smear  UPMC Magee -Womens Hospi[INVESTIGATOR_530151]# 39D0177794  
 
 
 
 
 
 
CVL Levels of antiviral activity  Magee -Womens Research Institute/ Parikh 
Laboratory  
(non-diagnostic laboratory)  
Levels of glycoproteins and 
mucins  Magee -Womens Research Institute/Moncla 
Laboratory (non -diagnostic laboratory)   
Levels of cytokines & innate 
immunity factors  Magee -Womens Research Institute/Hillier 
Laboratory  
(non-diagnostic laboratory)  
MK-2048 level  University of Colorado  
(non-diagnostic laboratory)  
Eudragit® level  University of Colorado  
(non-diagnostic laboratory)  
      *Future Use Samples will be stored at Magee -Womens Research Institute; use and processing lab to be determined  
11.1.[ADDRESS_688576] 
infection  as clinically indicated .  Urine will be tested for HCG via the Sure -Vue® test or equivalent . 
 
11.1.2 Vaginal Samples  
The assessment of vaginal flora will be based on the Nugent Scoring System for Gram Stained 
Vaginal Smears as well as assessment of severa l groups of organisms  by [CONTACT_280984] (culture) 
based methods .  In addition, selected microbiota will be detected using a quantitative polymerase 
chain reaction (qPCR) test which has been developed and validated within the laboratory.  MK-
[ADDRESS_688577] an adequate sample 
that is unlikely to disturb the mucosa or overall vaginal microenvironmen t or the vaginal film in 
situ.  Trichomonas vaginalis  will be detected using an amplified DNA assay and handled 
according to policies outlined in SOPs for this study.  
 
11.1.3 Rectal Swabs  
MK-2048 concentrations will be quantified according to the SOP . 
 
11.1.4 Cervical Samples  
C. trachomatis  and N. gonorrhoeae   will be detected using an amplified DNA assay and handled  
according to policies outlined in SOPs for this study.  
 
Pap smears collected as part of screening will be processed and resulted by [CONTACT_530182] -
Womens Hospi[INVESTIGATOR_530152].  
  
11.1. 5 Cervicovaginal Lavage Samples  
MK-2048  Content in CVL  
Aliquots of lavage samples will be tested for MK-2048  levels  (according to SOP).   
                                                                                                                    Page 45 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
Eudragit® Content in CVL  
Aliquots of lavage samples will be tested for Eudragit® levels (according to SOP)  
 
Anti-viral Activity in CVL  
Aliquots of lavage samples will be tested for anti -viral and antibacterial activity as  outlined in the 
site SOPs .  
 
Cervical Cytokines and Innate Factors in CVL  
Cytokines (for example, IL -1β and TNFα) along with innate immune factors (for example, 
antiproteases) that could contribute to a proinflammatory milieu or changes in the glycomic 
signatures may be evaluated.  The factors to be analyzed will be determined on the scientific 
evidence at the time of the analysis.  
 
Glycome Studies  
Aliquots of lavage samples will be tested for glycoproteins  and mucins . 
 
11.1.[ADDRESS_688578] of Medical Microbiol ogy (ABMM) , directs the Infectious Disease 
Research Laboratory at Magee -Womens Research Institute.  This laboratory is CLIA -inspected 
and maintains its own CLIA license.  Thus, all testing done in this research laboratory is performed 
with the same level o f quality control as required in a licensed clinical laboratory.   
 
11.3 Specimen Storage and Possible Future Research Testing  
Part of the consent form will include an explanation of future use of vaginal and cervical specimens 
and blood samples.  Any future us e or residual  samples will be stored at Magee -Womens 
Research Institute, Microbiology Laboratory, 5th floor for an indefinite period of time.  The principal 
investigator [INVESTIGATOR_280943].  
 
Any results from researc h done on  future use or  leftover specimens will not be placed in health 
records and will be kept confidential . The language and format employed in the consent for these 
purposes are an IRB -approved means commonly employed in studies performed at this and other 
study sites within our institution to obtain permission for use of stored samples.  All primary study 
endp oints, protocol -specified testing, and QA/QC testing will be ascertained prior to any additional 
testing of stored specimens.   
 
11.[ADDRESS_688579] the protocol and the protocol consent form(s) approved, as appropriate, by [CONTACT_530183] (IRB)/ethics committee (EC) and any other applicable regulatory 
entity (RE). Upon receiving final approval, the site will submit all required protocol registration 
documents to the DAIDS PRO at the Regulatory Support Center (RSC).  The DAIDS PRO will 
review the submitted protocol registration packet to ensure that all of the required documents 
have been received.  
 
Site-specific informed consent forms (ICFs) WILL NOT be reviewed or approved by [CONTACT_530184], and sites will receive an Initial Regist ration Notification when the DAIDS PRO receives a 
complete registration packet. Receipt of an Initial Registration Notification indicates successful 
completion of the protocol registration process. The site will not receive any additional notifications 
from the DAIDS PRO for the initial protocol registration. A copy of the Initial Registration 
Notification should be retained in the site's regulatory files.  
 
Upon receiving final IRB/EC and any other applicable RE approval(s) for an amendment, the 
study site should implement the amendment immediately. The site is required to submit an 
amendment registration packet to the DAIDS PRO at the RSC. The DAIDS PRO will review the 
submitted protocol registration packet to ensure that all the required documents have bee n 
received. Site -specific ICF(s) WILL NOT be reviewed and approved by [CONTACT_530185] a complete 
registration packet. A copy of the Amendment Registration Notification should be retained in the 
site's regulatory files.  
 
For additional information on the protocol registration process and specific documents required 
for initial and amendment registrations, refer to the current version of the DAIDS Protocol 
Registration Manual, available at http://rsc.tech -res.com/protocolregistration/    
 
12.[ADDRESS_688580] Research 
(ECO -HSR) will assist with the monitoring as outlined in the study monitoring plan.  
 
The site investigator will make study documents (e.g., consent forms, drug distribution forms, 
eCRFs) and pertinent hospi[INVESTIGATOR_530153], 
the site monitors, the FDA, NIAID/DAIDS, the OHRP, and other local, US, or international 
regulatory entities for confirmation of the study data.  
 
 
12.4 Protocol Compliance  
All protoc ol amendments will be submitted to and approved by [CONTACT_32928][INVESTIGATOR_280944].  
                                                                                                                    Page 47 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  
12.5 Investigator’s Records  
The investigator will maintai n, and store securely, complete, accurate and current study records 
throughout the study.  Study records will not be destroyed prior to receiving approval for record 
destruction from the Principal Investigator [INVESTIGATOR_237256] a minimum of s even 
years following completion of the study, per the University of Pi[INVESTIGATOR_237257] .  Applicable 
records include source documents, site registration documents and reports, correspondence, 
informed consent forms, and notations of all contacts with the  participant.   
 
12.[ADDRESS_688581] counseling.   
                                                                                                                    Page 48 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
  REFERENCES  
1. UNAIDS 2017 Global HIV and AIDS Statistics. Accessed at 
https://www.unaids.org/en/resources/fact -sheet     
2. UNAIDS Women and Girls and HIV. Accessed at 
https://www.unaids.org/site s/default/files/media_asset/women_girls_hiv_en.pdf  
3.  Steiner M, Spruyt A, Joanis C, et al. Acceptability of spermicidal film and foaming tablets among 
women in three countries. International Family Planning Perspectives 1995;21:104 -7. 
4. Visness CM, Ulin P, Pfannenschmidt S, Zekeng L. Views of Cameroonian se x workers on a woman -
controlled method of contraception and disease protection. Int J STD AIDS 1998;9:695 - 
5. Nel AM, Mitchnick LB, Risha P, Muungo LT, No rick PM. Acceptability of vaginal film, soft -gel 
capsule, and tablet as potential microbicide delivery  methods among African women. J Womens Health 
(Larchmt) 2011;20:1207 -14. 
6.  Raymond E, Alvarado G, Ledesma L, et al. Acceptability of two spermicides in five countries. 
Contraception 1999;60:45 -50. 
7.  Montgomery E , Beksinska M , Mgodi N , et al. End-user preference for and choice  of four vaginally 
delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro 
Clinical Crossover Study . J Int AIDS  Soc. 2019 May;22(5):e25283.  
8.          Magee -Womens Research Institute and Foundation MK-2048 30mg Extended Release Vaginal 
Film. 2019  
9. [COMPANY_006] Sharp & Dohme Corp. MK -[ADDRESS_688582], et al. Phase 1 safety and pharmacokinetics study of MK -2048/ 
Vicriviroc (MK -4176)/MK -2048A intravaginal  rings. Clinical Infectious Disease 2019;68:[ADDRESS_688583], et al. Phase 1 pharmacokinetic trial of 2 intravaginal rings containing  
different dose strengths of Vicriviroc  (MK -4176) and MK -2048. Clinical Infectious Disease 2019;68:[ADDRESS_688584] C, Sharma S, Parikh UM, et al. Postexposure protection of macaques from vaginal SHIV 
infection by [CONTACT_12523][INVESTIGATOR_530154] . Sci Transl Med . 2014 Mar 12;6(227):227   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
                                                                                                                    Page 49 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 APPENDIX 1:  SCHEDULE OF STUDY VISITS AND PROCEDURES  
Component  Procedure/Analysis  V1:  
Screen  V2:  
Enroll  V3-7 V8 
 
 
 
 
 
 
ADMINISTRATIVE  Written Informed Consent  X    
Assign Study Number (PTID)  X    
Review/Confirm Eligibility  X X   
Collect/Update Contact [CONTACT_7171]  X X X X 
Medical Hx/Concomitant Meds  X X X X 
Visit Questionnaire  X X X X 
HIV Pre -/Post -Test Counseling  X    
Screening Results  X X   
Protocol counseling  X X X  
Assess/Document Adverse Events   X X X 
Schedule Next Study Visit  X X X  
Participant Reimbursement  X X X X 
ACCEPTABILITY  Acceptability Questionnaire   X V5 ONLY   
 
URINE  Pregnancy test  X X ^ & V5  X 
Urine dipstick  ^ ^ ^ ^ 
SALIVA  Rapid HIV  X    
BLOOD  Confirmatory HIV  ^    
MK-2048 levels   X* X X 
 
 
 
VAGINAL  SAMPLES  
 pH X X X X 
Wet Mount  ^ ^ ^ ^ 
Trichomonas (NAAT)  X  ^ ^ 
Gram Stain   X X X 
Quantitative Vaginal Culture   X X X 
Quantitative PCR for microbiota   X X X 
Vaginal Sample  for Future Use** X X X X 
MK-2048 ® level  X* X X 
 
CERVICAL  SAMPLES  GC/CT (NAAT)  X  ^ ^ 
Cervical S ample  for Future Use ** X X X X 
Pap smear  ^    
Cervical Biopsies    V5 ONLY   
RECTAL  SAMPLES  MK-2048 level    V5 ONLY   
 
 
CVL Levels of antiviral activity  X  V7 ONLY  X 
Glycoproteins and mucins  X  V7 ONLY  X 
Cytokines & innate immunity 
factors  X  V7 ONLY  X 
Eudragit® level  X  V7 ONLY  X 
MK-2048 level  X  V7 ONLY  X 
 
PHYSICAL  EXAM  Physical Exam  X ^ ^ ^ 
Vital Signs (BP)  X X X X 
Height & Weight  X    
 
PELVIC EXAM  Bimanual Exam  ^ ^ ^ ^ 
External Genital & Speculum Exam  X X X X 
STUDY PRODUCT  Study Product Randomization   X   
Film Distribution   X   
Film Insertion  by [CONTACT_9142]   X   
X Required           
^ PRN/as clinically indicated  
* Additional OPTIONAL vaginal swabs (up to 2) and single blood sample at 1, 2, 3, 4, 5, 6hrs post film   
   Insertion  
** For participants who have consented to the collection of samples for future use and use of left -over samples for future studies.  
                                                                                                                    Page 50 of 59 
 
  FAME 103 Protocol Version 1.0 20Dec 2019                                                                      
 APPENDIX II:  HIV TESTING AGORITHIM  
 
  START  
SAMPLE 1  
OraQUICK® Rapid 
HIV Test  IF 
NEGATIVE  
→ STOP  
REPORT AS HIV -
UNINFECTED; 
ENROLL IN STUDY  
   
IF POSITIVE   
 
 
   ↓  
REPORT AS 
INDETERMINATE,  
REQUIRES 
ADDITIONAL 
TESTING  IF  
INDET.  
← SAMPLE 2  
HIV Ab/Ag Plasma 
Testing  IF 
NEGATIVE  
 
   
IF POSITIVE    
  ↓   
  REPORT AS HIV -
POSITIVE,  
REQUIRES 
CONFIRMATORY 
TESTING  
   
  ↓   
  REFERRALFOR 
CARE  
   
     
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                                    Page 51 of 59 
 
 
FAME 103 Protocol Version 1.020Dec 2019  
 
 
 
 
 
 
 
 
  
APPENDIX  III:  SAMPLE INFORMED CONSENT  
 
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY  
  
STUDY TITLE:    A Randomized, Double Blinded Study of the Safety and Pharmacokinetics of Two 
Vaginal Film Formulations Containing the Integrase Inhibitor MK2048:  FAME 103  
 
INFORMED CONSENT VERSION:   Version 1.0, 12/20/2019  
 
PRINCIPAL INVESTIGATOR:   [INVESTIGATOR_530155], MD  
    UPMC Magee -Womens Hospi[INVESTIGATOR_307], Dept of OB/GYN/RS,  
    [ADDRESS_688585], PGH, PA  [ZIP_CODE]  
 
QUESTIONS ABOUT THE STUDY:  Contact [CONTACT_52903] 412 -641-4242 or after hours at 412 -463-
1337  
 
FUNDING AGENCY:   Division of AIDS, US National Institute of Allergy and Infectious Diseases, US National 
Institutes of Health  
 
 
KEY INFORMATION  
Participation is voluntary.  You are being asked to take part in a research study.   Research studies include 
only people who choose to take part.   The study team members will explain the study to you and will answer 
any questions you might have.   You should take your time to make you r decision.  
 
Summary of study . This study includes approximately 48 healthy non -pregnant women aged 18 – 45 who 
agree to use a single investigational (experimental) vaginal film and return for 6 follow up visits.  The vaginal 
film, which is a thin square s imilar to a Listerine® breath strip,  contains an investigational medication called 
MK2048.  MK2048 is not approved by [CONTACT_2165] (FDA). This study will assess the 
safety and acceptability of the film.    
 
Visits (8 in total)  Time  Key component(s) of visit  
Screen  Today  Determine eligibility; includes STD/HIV testing  
Enrollment  Within 45 days  Vaginal film insertion by a clinician  
Required Follow -up Visits  Days 3, 5, 7, 10, 14, 
28 Blood and genital * sample collection at each visit; 
Cervical biopsies and rectal swabs at Day 7 visit only  
*Genital samples refer to vaginal, cervical and/or rectal samples   
 
Risks. The main risks of participation include the risks of using an investigational vaginal film, blood draws and 
cervical biopsies.  The number of study visits may be inconvenient.   
 
Benefits.  There is no direct benefit to participating, however some particip ants may get satisfaction taking part 
in a study that involves women’s health.  
 
                                                                                                                    Page 52 of 59 
 
 
FAME 103 Protocol Version 1.020Dec 2019  
 
 
 
 
 
 
 
 
 Right to withdrawal.  You may withdraw from the study at any time if you chose.   
 
Alternatives.  The alternative is not to participate in this study.     
 
******************* *********************************************************************  
YOUR PARTICIPATION IS VOLUNTARY  
Participation in research is a personal decision; you are under no obligation to participate.  If you agree to take 
part, you will be asked to sign your n ame on this form and will be offered a copy to keep.  Your regular doctor 
may be part of this study team.  You should take your time to make a decision and discuss with others if needed.  
 
STUDY PRODUCTS AND PURPOSE OF STUDY  
Two different vaginal films will  be tested in this study.  Both films contain the same amount of an investigational 
medication called MK2048.  MK2048 has been used in other studies to look at HIV prevention.  The two films 
differ in the amount of polymer (“binding” or “delivery” agent).   
 
Films  MK2048 dose  Size # of participants  
high polymer*  30mg  2” x 2”  24 
low polymer  30mg  2” x 2”  24 
*used in a previous placebo (blank, no drug) film study of 64 women and was safe and acceptable    
 
The Food and Drug Administration (FDA) has not approved MK2048 film for use.  While MK2048 has been 
tested in humans, including vaginal dosing via vaginal ring, this is the first time MK2048 has been tested in a film 
form in humans. Importantly, all the in gredients that make up the film, including the polymers have been tested 
in humans and have been found to be safe.   
 
This study is testing the safety of MK2048 film when used once.  Cervical biopsies, vaginal and rectal samples, 
and blood will be collecte d to see how much MK2048 gets into the genital tissue and/or bloodstream.  The 
cervical tissue will be exposed to HIV in the lab  to understand whether the film can help to prevent HIV infection 
when tested outside the body.   
 
This study is not testing if MK2048 vaginal  film prevents you from getting infected with HIV.  R esearchers do not 
yet know if the film will work in humans to protect against HIV.  The best way to protect against getting HIV 
infection during sex is to use a condom every time you have s ex. 
 
Eligible women will be randomized (50/50 chance, like flippi[INVESTIGATOR_007] a coin) at visit 2 (V2) to have one of two films 
inserted (high polymer or low polymer).  You cannot choose your group.  Both films are packaged identically, so 
neither you nor study staff  will know which group you are in.  All women will follow the same study visit schedule.  
 
 
STUDY VISIT HIGHLIGHTS  
• All research activities will take place at UPMC Magee -Womens Hospi[INVESTIGATOR_307].  
• A screening visit (V1) will determine if you are eligible to participa te.  You are under no obligation to 
participate even if you are found to be eligible.  Screening can occur over more than one visit, if necessary.  
• If eligible and interested, you will be asked to return within 45 days to be enrolled (V2).  At V2, you will have 
the assigned vaginal film inserted into the vagina by a research clinician.   
                                                                                                                    Page 53 of 59 
 
 
FAME 103 Protocol Version 1.020Dec 2019  
 
 
 
 
 
 
 
 
 • There are 6 follow -up visits (V3 – V8).  Window periods for visi ts will allow some flexibility in scheduling 
study visits.  Genital and blood samples are collected to establish your baseline and to check drug levels 
throughout the study.   
•  
    This table outlines the visit schedule and study procedures.   
 
STUDY PROCEDURES  STUDY VISIT  
SCREEN  ENROLL  FOLLOW -UP 
V1 V2 V3 V4 V5 V6 V7 V8 
Day -45 0 3 5 7 10 14 28 
Length of Visit  1hr 1hr 30m 30m 30m 30m 30m 30m 
Medical History & Medication 
review  x x x x x x x x 
Visit Questionnaire  x x x x x x x x 
Collect/update contact [CONTACT_3031]  x x x x x x x x 
HIV Rapid Test  x        
HIV Confirmatory Test  ^        
Review Applicable Test Results  x x       
Protocol Counseling  x x x x x x x  
Urine pregnancy test  x x   x   x 
Blood draw (MK2048 level)   x x x x x x x 
Pelvic Exam with speculum  x x x x x x x x 
Genital sample collection  x x x x x x x x 
STD testing  x        
Pap smear  ^        
CVL (vaginal “wash” with saline)  x      x x 
Cervical Biopsies      x    
Rectal Swab (MK2048 level)      x    
Brief Physical Exam  x        
Height and Weight  x        
Blood pressure  x x x x x x x x 
MK2048 Film Insertion (by 
[CONTACT_30223])   x       
Acceptability Questionnaire   x   x    
Compensation  $30 $40 $30 $30 $100  $30 $30 $40 
Incentive if all visits in window         $40 
Optional procedures   *       
 
^ as necessary  
* V2 INCLUDES OPTIONAL SAMPLING: You may choose to have up to two  vaginal swabs collected without a 
speculum and one blood sample collected following film insertion.   
o Optional collection times are at 1, 2, 3, 4, 5, or 6 hours following film insertion.   
o Additional compensation will be provided for each sample collected as follows:  
 1, 2, 3 hour collection  4, 5, 6 hour collection  
Vaginal Swab  $10 $20 
                                                                                                                    Page 54 of 59 
 
 
FAME 103 Protocol Version 1.020Dec 2019  
 
 
 
 
 
 
 
 
 Blood Sample  $20 $30 
 
 
ADDITIONAL STUDY VISIT PROCEDURE INFORMATION  
• Visit Questionnaires include asking things like sexual history, vaginal product use, and vaginal symptoms  
• HIV testing will be done as part of the study.  
o A saliva sample will be tested for the antibody to HIV. An antibody is a substance that blood cells 
make to fight infection. Exposure (contact) to the HIV virus produces antibodies.  
o Results take [ADDRESS_688586] HIV, you cannot join the study.  You will be referred for medical care and 
other services.  Your partner(s) may have access to free HIV counseling and testing, if needed.  
• You will only get the results of tests that are applicable to your clinical care , including pregnancy test, STD 
and HIV tests, and evaluation for vaginal complaints if performed.  You will not get the results of the other 
tests as they are done for research purposes only.  
• Protocol counseling includes visit reminders, STD/HIV and abst inence counseling, and vaginal product use.  
o You must agree to not have sex (vaginal, anal and receptive oral) from V2 – V7. 
o You must also agree to not have sex [ADDRESS_688587] agree not to use vaginal products during the s tudy and no tampon use between V5 – V7. 
• Blood will be drawn to test MK2048 levels.  Approximately 2 teaspoons of blood will be drawn each time.  
• Genital sample collection includes collecting Q -tip like swabs from the vagina, cervix and rectum.  The 
samples  will be used to look at bacteria and other markers.  
• STD (sexually transmitted disease) testing will include Chlamydia, Gonorrhea and Trichomonas.  
• CVL (cervicovaginal lavage) is a vaginal “wash” of the vagina with saline; the wash takes one minute.  
• Cervic al biopsies will be collected by a physician investigator at V5.  
o Two adequate samples will be collected, approximately 3mm each or the size of a grain of rice.  
o The biopsy sites take approximately 7 days to heal.  As a reminder, do not put anything in the 
vagina (tampon, sex toy) and avoid any type of sex (vaginal, anal, receptive oral) for 7 days.  
• Study procedures can be repeated as needed (e.g. collection or processing error , or for clinical reasons ). 
• Microscopic exam (looking under a microscope) of vagina l discharge, urine dipstick and bimanual exam (to 
feel uterus and ovaries) may be done as clinically indicated during the study.  
• Interim or unscheduled visits may occur if needed (e.g. abnormal results, repeat testing, side effects).  
• Study participation for the required visits end at Visit 8 (Day 28).  
• If you have ongoing side effects at V8, study staff may call you until the issue stabilizes or resolves.  
• In the unlikely event you become pregnant while participating in the study, the study staff will refer  you for 
appropriate care.  You will be exited from the study, but study will  need to follow up with you by [CONTACT_530186].  
• If you are found to have an Gonorrhea, Chlamydia or Trichomonas or a vaginal infection during the study, 
you may be provided with directly observed antibiotic treatment . 
• The samples for this research study will be sent to Magee -Womens Research Institute (MWRI) where most 
of the samples will be processed.  Some samples may be sent t o outside investigators for processing or 
                                                                                                                    Page 55 of 59 
 
 
FAME 103 Protocol Version 1.020Dec 2019  
 
 
 
 
 
 
 
 
 analysis.  Importantly and regardless of lab, all samples are sent with a unique study number.  No personal 
identifiers (name, SSN, birthdate) will be on the samples.   
RISKS AND/OR DISCOMFORTS  
By [CONTACT_530187], you could have these side effects or other side effects that we do not know about.  
Procedure  Risk  
Pregnancy Test  • Anxious or nervous having test or waiting for results  
• Denial, depression or worry with unexpected positive result  
Pelvic Exam  • Discomfort with speculum  
Genital and rectal 
specimens  • Minimal discomfort from collection of specimens  
Cervical Biopsy  • Generally well tolerated but may cause pain (or pi[INVESTIGATOR_38633])  
• Crampi[INVESTIGATOR_530147]  
o Crampi[INVESTIGATOR_530148]  
o May take ibuprofen prior to biopsy to minimize crampi[INVESTIGATOR_007]  
• Vaginal spotting or bleeding for a couple days  
o Typi[INVESTIGATOR_15120] a period but if heavier, contact [CONTACT_464]  
• Infection of biopsy area  
o Unlikely but if foul odor or unusual di scharge, contact [CONTACT_464]  
• A cut in the vagina can put you at increased risk of getting HIV if exposed  
• If you have an IUD, there is a risk of dislodging it with performing the biopsies.  If 
displaced, a new IUD will be inserted at no cost to you  
Vaginal  use of  
MK 2048 film  • Vaginal discharge, irritation, discomfort  
• Vaginal burning, itching, redness and/or pain;  
• Yeast or vaginal infection  
• Allergic reaction  
Blood draw  • Bruising, soreness, pain/discomfort, bleeding, infection at the site  
• lightheadedness, fainting  
Participation in 
research ; 
collection and 
storage of private 
health information, 
biospecimens and 
internet 
communication * • Inconvenient  
• Breach of confidentiality  
Questionnaires  • Discomfort with personal nature of questions  
STD/HIV testing  • Worry or anxiety  
• Sadness, depression or denial with a positive test result  
o Positive gonorrhea and chlamydia test results will be reported to ACHD 
according to the Commonwealth of Pennsylvania reporting requirements  
o May be contact[CONTACT_530188]  
*We will make reasonable efforts to protect the privacy of information on social media. Each platform has their 
own privacy policies and terms of use that may change at any time. The University of Pi[INVESTIGATOR_530156]. Your  
                                                                                                                    Page [ADDRESS_688588] agree to avoid sexual intercourse 
from V2 (enrollment) until V7 (7 days after the biopsy visit),  and [ADDRESS_688589] scheduled pregnancy  tests while in the study. Effective methods of birth control 
include hormonal methods (like "the pi[INVESTIGATOR_4382]" or Depo -Provera injections), the IUD, sterilization (or "tied tubes"), 
abstinence (or not having sex), same sex partner, or having a partner who has had  a vasectomy. You must 
agree to use this method of birth control until the last study visit, approximately [ADDRESS_688590] your health while you are pregnant. The outcome of your pregnancy is important to study staff; you 
will be followed through the outcome of your pregnancy.  
 
If you were to become HIV infected while using the study product, the HIV virus may develop resistance to 
MK2048.  Developi[INVESTIGATOR_270196]2048 resistance means that the MK2048 may not be able to treat HIV however, 
MK2048 is not currently used to treat HIV.  
 
BENEFITS  
You will not  directly benefit from participating in this study.  You may, however, feel satisfaction knowing that 
information learned from this study may help in the development of vaginal products for women.  You will also 
have exams and HIV/STD testing as  part of your participation in this study.      
 
NEW INFORMATION  
You will be told about any new information learned that might affect your willingness to stay in the study.   
 
CLINICALLY RELAVENT RESEARCH RESULTS :  You will be given the results of your pre gnancy, STD and 
HIV testing.  Counseling, referrals and treatment will be discussed as applicable.  There is no plan to provide 
you with your results for tests collected for research purposes only or results of the study in general once it is 
completed.  
 
STOPPI[INVESTIGATOR_530157]:  
• The study is stopped or cancelled  
• You are not able to keep appointments  
                                                                                                                    Page 57 of 59 
 
 
FAME 103 Protocol Version 1.020Dec 2019  
 
 
 
 
 
 
 
 
 • Other reasons that may prevent you from completing the study successfully or safely . This would include 
a newly diagnosed pregnancy or HIV.   If you become pregnant, although you will be terminated from 
further study visits, study staff will continue to contact [CONTACT_530189].   
Participants who withdraw or who are withdrawn from the study prior to completing follow up may be asked to 
complete a final study visit.   
 
COSTS TO YOU  
There is no cost to you or your insurance for study related visits or procedures.   
 
REIMBURSEMENT  
You will receive compensation for your time, effort, and travel expenses as detailed in the study procedure table 
above.  If you complete all the required study visits within the designated window periods, you will receive a total 
of $370.  If you complete  all the required study visits and the optional V2 procedures, it is possible to be 
compensated up to $440.   If you complete a visit but are seen outside of the protocol window for that visit, $[ADDRESS_688591] your confidentiality.  The link 
to your name [CONTACT_530198] a separate, secure location that only the clinical research team 
has access to.  If data from this study is shared with other (outside) investigators interested in infections, the 
information will be shared without personal identifiers  (for example name, date of birth, SSN) .   
 
In unusual circumstances, your research re cords may be inspected by [CONTACT_530190]. The University of 
Pi[INVESTIGATOR_530158] (ECO -HSR)  may review your 
identifiable research information (which may include your identifiable medical record information) for the 
purpose of monitoring the appropriate conduct of this research study.  The sponsor of the study or their 
designee may also review yo ur identifiable research information but only for the purposes of monitoring the 
conduct and data collected for the study.  No information will be extracted from your medical record unless you 
sign a separate medical release and no information about your p articipation in this study will be placed in your 
medical record.  
 
We will do everything possible to keep your test results confidential but this cannot be guaranteed.  If others 
would become aware of your HIV status, it could result in discrimination whi ch may impact your employability, 
insurability, or even prevent you from traveling to certain countries.  If you test positive, Pennsylvania state law 
requires your name [CONTACT_530199]. A ll information will be handled  in 
compliance with the Pennsylvania law on HIV -related confidential information.  
 
If you test positive for gonorrhea, chlamydia, or HIV, the Commonwealth of Pennsylvania requires that your 
name [CONTACT_280999].  You may be contact[CONTACT_530191](s).  
 
                                                                                                                    Page 58 of 59 
 
 
FAME 103 Protocol Version 1.020Dec 2019  
 
 
 
 
 
 
 
 
 The investigators may use or disclose, for purposes described above, identifiable information (which may include 
identifiable medical information) related to your being in this study a minimum  of 7 years and for as long 
(indefinite) as it may take to complete this study.  
 
A description of this clinical trial will be available on http://www.clinicaltrials.gov. This website will not include 
information that can identify you. At most, the website will include a summary of the results. You can search this 
website at any time.  
 
Your participation in this study may include whole genome sequencing.  Whole genome sequencing is the 
mappi[INVESTIGATOR_530159] a person’s unique DNA. Your genome is the unique blueprint  for your body. Sometimes, because 
of new or inherited genetic mutations, your genes can cause a disease or increase your risk for disease. By 
[CONTACT_530192], health professionals can look at the unique variations found in your genes. Some of 
it ma tters. Some doesn’t matter. Some is still unknown or uncertain.  
 
RESEARCH -RELATED INJURY  
If you believe that the research procedures have resulted in an injury to you, immediately contact [CONTACT_9532] [INVESTIGATOR_530160] f orm.  Emergency medical treatment for injuries solely and 
directly related to your participation in this research study will be provided to you by [CONTACT_5035][INVESTIGATOR_132121].  Your 
insurance provider may be billed for the costs of this emergency treatment, but none of those costs will be 
charged directly to you.  If your research  related injury requires medical care beyond this emergency treatment, 
you will be responsible for the costs of this follow -up care.  At this time, there is no plan for any additional fi nancial 
compensation.  You do not give up your legal rights by [CONTACT_3368]. The US National Institutes of Health 
(NIH) does not have a mechanism to provide compensation for research related injury.    
 
HIPAA AUTHORIZATION:  We are requesting your aut horization or permission to access your protected 
health information for research purposes.  This authorization will be valid for an indefinite period of time.  We 
may obtain information concerning your birth control method, age, level of education, past m edical and 
gynecologic history and results of any tests that were already done as part of your standard evaluation.   
 
This information may be needed so that we can compare the data in your medical record to the data obtained 
for this study.  We may use the information to identify whether you meet the conditions for participation in this 
study.  We may also use your medica l record to obtain new contact [CONTACT_530193]. The information may be needed for retention purposes.   
 
The identifiable information will be made available to members of the research team, for an indefinite period of 
time an d may be shared with other groups, possibly including authorized representatives of the sponsor of the 
study, National Institutes of Health (or authorized representative that they delegate, such as representatives 
from monitoring or auditing companies) or authorized officials from the University of Pi[INVESTIGATOR_530161].  We will protect your privacy and the confidentiality of your records, as 
described in this document but cannot guarantee the confidentiality of your research re cords, including 
information obtained from your medical records, once your personal information is disclosed to others outside 
UPMC or the University.   
 
Your research information and data may be shared with investigators conducting other research.  The sh ared 
information may be labeled by [CONTACT_530194] [ADDRESS_688592] in w riting.  If you do so, you will no 
longer be permitted to participate in this study.  Any information obtained from you up to that point will continue 
to be used by [CONTACT_5051].   
 
YOUR RIGHTS AS A RESEARCH PARTICIPANT/VOLUNTEER  
Your participation in  this research study is entirely voluntary.  You may want to discuss this study with your 
family and friends and your personal physician before agreeing to participate.  If there are any words you do 
not understand, feel free to ask us.  The investigators will be available to answer your current and future 
questions.   
 
Whether or not you provide your consent for participation in this research study will have no effect on your current 
or future relationship with the University of Pi[INVESTIGATOR_9109], your current or  future medical care at a UPMC hospi[INVESTIGATOR_530162] a health care insurance provider.  
 
CERTIFICATE OF CONFIDENTIALITY:  
To help us protect your privacy, we have obtained a Certificate of Con fidentiality from the National Institutes of 
Health.  The researchers can use this Certificate to legally refuse to disclose information that may identify you 
in any federal, state, or local civil, criminal, administrative, legislative, or other proceeding s, for example, if 
there is a court subpoena.  The researchers will use the Certificate to resist any demands for information that 
would identify you, except as explained below.   
 
The certificate cannot be used to resist a demand for information from pers onnel of the [LOCATION_002] 
Government that is used for auditing or evaluation of federally -funded projects or for the information that must 
be disclosed in order to meet the requirements of the US Food and Drug Administration (FDA) and other 
regulatory aut horities.  
 
You should understand that a Certificate of Confidentiality does not prevent you or a member of your family 
from voluntarily releasing information about yourself or your involvement in this research.  If an insurer, 
employer, or other person ob tains your written consent to receive research information, then the researchers 
may not use the Certificate to withhold that information.   
 
The Certificate of Confidentiality will not be used to prevent disclosure to state or local authorities of child abuse 
and neglect, or harm to self or others.  
 
PROBLEMS OR QUESTIONS  
If you ever have any questions about the study, or if you have a research -related injury, you should contact 
[INVESTIGATOR_530155], MD or the research staff at (412) [ADDRESS_688593] the University of Pi[INVESTIGATOR_280954] 1 -[PHONE_2954].    
 
  
                                                                                                                    Page [ADDRESS_688594] infections, for further understanding of STDs and how the body 
responds to infection and/or genetic testing and may include whole genome sequencing .  Whole genome 
sequencing is the mappi[INVESTIGATOR_530159] a person’s unique DNA. Your genome is the unique blueprint for your body. 
Sometimes, because of new or inherited genetic mutations, your genes can cause a disease or increase your risk for 
disease. By [CONTACT_530192], health professionals can look at the unique variations found in your gene s. Some of 
it matters. Some doesn’t matter. Some is still unknown or uncertain.    
 
The specimens would be stored at Magee Womens Research Institute by [CONTACT_5056]; your name [CONTACT_530200].  Information linking your study number to your name [CONTACT_530201] a separate, secure location 
in the clinical research area.   
 
Your study samples or genetic material may lead, in the future, to new inventions or products.  If the research 
investigators develop new products from the use of your biologic sam ple or genetic material, there are 
currently no plans to share with you any money or other rewards that may result from the development of the 
new product.    
 
You would not be informed of results of the future tests since the data may not be applied to a clinical setting 
and may not affect clinical care.  Any results from the research done on future use samples would not be put in 
your medical record and would be kept confidential.  Samples may be given to other investigators (secondary 
investigators), oth er than Magee and UNC investigators.  If samples were given to secondary investigators 
they would be made available without links to your personal identifying information.  
 
There are few risks to you from future use of your specimens.   Reports about resea rch done with your 
specimens will not be put in your health record, but will be kept with the study records.  Results from future 
research using your specimens may be presented in publications and meetings, but your name [CONTACT_530202].  
 
PLEASE INITIAL  YOUR CHOICE BELOW (chose one):  
 
 
_________        I agree to the future use of my specimens as described above  
                  initials  
                                                                                  OR 
_________      I DO NOT agr ee to the future use of my specimens as described above  
     initials  
 
*****************************************************************************************   
                                                                                                                    Page 61 of 59 
 
 
FAME 103 Protocol Version 1.020Dec 2019  
 
 
 
 
 
 
 
 
 PLEASE INITIAL  WHICH, IF ANY, OPTIONAL RESEARCH PROCEDURES YOU AGREE TO BELOW :  
 
Optional Procedure  Visit Timepoint(s)  Initial if you agree  
Up to two additional vaginal swab(s)  V2 
Enrollment  1, 2, 3, 4, 5, 6 hrs after film 
placement   
One additional blood sample  V2 
Enrollment  1, 2, 3, 4, 5, 6 hrs after film 
placement   
 
******************************************************************************************  
VOLUNTARY CONSENT  
The above information has been explained to me and all of my current questions have been answered.  I 
understand that I am encouraged to ask questi ons, voice concerns or complaints about any aspect of this 
research study during the course of this study, and that such future questions, concerns or complaints will be 
answered by a qualified member of the research team or by [CONTACT_458] l isted on the first page.  I 
understand that I may always request that my questions, concerns or complaints be addressed by [CONTACT_9532].  At any time I may also contact [CONTACT_132133], 
University of P ittsburgh (1 -[PHONE_2954]) to discuss problems, concerns and questions; obtain information; offer 
input; or discuss situations in the event that the research team is unavailable.  By [CONTACT_3368] I agree to 
participate in this research study for the p urposes described above.  A copy of this consent form will be offered 
to me.  
 
_______________________________________   
Printed Name [CONTACT_2385]    
 
                      
_______________________________________  _________________     ______________   
Participant Signature      [CONTACT_530203]/PM  
 
CERTIFICATION OF INFORMED CONSENT:  I certify that I have explained the nature and purpose of this 
research to the above individual and I have discussed the potential benefits and possible risks of study 
participation.  Any questions the individual has about this study have been answered, and we will always be 
available to address future questions as they arise.  I further certify that no research component of this protocol 
was begun until after this consent f orm was signed.  
 
 
________________________________________   ____________________  
Printed Name [CONTACT_132136]  
 
 
________________________________________   ____________________  
Signature [CONTACT_525065] 